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A B S T R A C T
Background
Outcome after spontaneous (non-traumatic) intracerebral haemorrhage (ICH) is influenced by haematoma volume; up to one-third
of ICHs enlarge within 24 hours of onset. Early haemostatic therapy might improve outcome by limiting haematoma growth. This is
an update of a Cochrane Review first published in 2006, and last updated in 2009.
Objectives
To examine 1) the effectiveness and safety of individual classes of haemostatic therapies, compared against placebo or open control, in
adults with acute spontaneous intracerebral haemorrhage, and 2) the effects of each class of haemostatic therapy according to the type
of antithrombotic drug taken immediately before ICH onset (i.e. anticoagulant, antiplatelet, or none).
Search methods
We searched the Cochrane Stroke Trials Register, CENTRAL; 2017, Issue 11, MEDLINE Ovid, and Embase Ovid on 27 November
2017. In an effort to identify further published, ongoing, and unpublished randomised controlled trials (RCT), we scanned bibliogra-
phies of relevant articles and searched international registers of RCTs in November 2017.
Selection criteria
We sought randomised controlled trials (RCTs) of any haemostatic intervention (i.e. pro-coagulant treatments such as coagulation
factors, antifibrinolytic drugs, or platelet transfusion) for acute spontaneous ICH, compared with placebo, open control, or an active
comparator, reporting relevant clinical outcome measures.
Data collection and analysis
Two authors independently extracted data, assessed risk of bias, and contacted corresponding authors of eligible RCTs for specific data
if they were not provided in the published report of an RCT.
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Main results
We included 12 RCTs involving 1732 participants. There were seven RCTs of blood clotting factors versus placebo or open control
involving 1480 participants, three RCTs of antifibrinolytic drugs versus placebo or open control involving 57 participants, one RCT of
platelet transfusion versus open control involving 190 participants, and one RCT of blood clotting factors versus fresh frozen plasma
involving five participants. We were unable to include two eligible RCTs because they presented aggregate data for adults with ICH
and other types of intracranial haemorrhage. We identified 10 ongoing RCTs. Across all seven criteria in the 12 included RCTs, the
risk of bias was unclear in 37 (44%), high in 16 (19%), and low in 31 (37%). Only one RCT was at low risk of bias in all criteria.
In one RCT of platelet transfusion versus open control for acute spontaneous ICH associated with antiplatelet drug use, there was a
significant increase in death or dependence (modified Rankin Scale score 4 to 6) at day 90 (70/97 versus 52/93; risk ratio (RR) 1.29,
95% confidence interval (CI) 1.04 to 1.61, one trial, 190 participants, moderate-quality evidence). All findings were non-significant for
blood clotting factors versus placebo or open control for acute spontaneous ICH with or without surgery (moderate-quality evidence),
for antifibrinolytic drugs versus placebo (moderate-quality evidence) or open control for acute spontaneous ICH (moderate-quality
evidence), and for clotting factors versus fresh frozen plasma for acute spontaneous ICH associated with anticoagulant drug use (no
evidence).
Authors’ conclusions
Based on moderate-quality evidence from one trial, platelet transfusion seems hazardous in comparison to standard care for adults with
antiplatelet-associated ICH.
We were unable to draw firm conclusions about the efficacy and safety of blood clotting factors for acute spontaneous ICH with or
without surgery, antifibrinolytic drugs for acute spontaneous ICH, and clotting factors versus fresh frozen plasma for acute spontaneous
ICH associated with anticoagulant drug use.
Further RCTs are warranted, and we await the results of the 10 ongoing RCTs with interest.
P L A I N L A N G U A G E S U M M A R Y
Treatments to help blood clotting to improve the recovery of adults with stroke due to bleeding in the brain
Review question
Do treatments to help blood clot reduce the risk of death and disability for adults with stroke due to bleeding in the brain?
Background
More than one-tenth of all strokes are caused by bleeding in the brain (known as brain haemorrhage). The bigger the haemorrhage,
the more likely it is to be fatal. Roughly one-third of brain haemorrhages enlarge significantly within the first 24 hours. Therefore,
treatments that promote blood clotting might reduce the risk of death or being disabled after brain haemorrhage by limiting its growth,
if given soon after the bleeding starts. However, haemostatic drugs might cause unwanted clotting, leading to unwanted side effects,
such as heart attacks and clots in leg veins.
Study characteristics
We found 12 randomised controlled trials, including 1732 participants, up to November 2017.
Key results
We found moderate-quality evidence of harm from platelet transfusion for people who had used antiplatelet drugs until they had a brain
haemorrhage. We found no evidence of either benefit or harm from other haemostatic therapies for people with brain haemorrhage.
Quality of the evidence
Overall, the quality of the evidence was moderate to low.
More information will become available from the 10 trials that are ongoing.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Blood clotting factors compared with placebo or open control for acute spontaneous intracerebral haemorrhage
Patient or population: adults with acute spontaneous intracerebral haemorrhage
Settings: secondary care
Intervention: recombinant act ivated factor VII
Comparison: placebo or open control
Outcomes Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Death or dependence (mRS 4 to
6) at day 90
RR 0.87 (0.70 to 1.07) 1390
(6)
⊕⊕⊕©
moderate¹
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
CI: conf idence interval; RR: risk rat io; mRS: modif ied Rankin Scale
¹We downgraded the quality of the evidence once because of imprecision.
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B A C K G R O U N D
Description of the condition
The burden of haemorrhagic stroke is out of proportion to its
frequency as a subtype of stroke. Although haemorrhagic stroke
causes 11% to 22% of all new strokes (Feigin 2009), it caused
50% of all stroke deaths, and approximately 42% (47 million)
of the disability-adjusted life years lost due to stroke in the 2013
Global Burden of Disease study (Feigin 2015). Spontaneous (non-
traumatic) intracerebral haemorrhage (ICH) accounts for two-
thirds of haemorrhagic stroke, amounting to more than two mil-
lion strokes per year (Al-Shahi Salman 2009a). ICH is due to
cerebral small vessel disease, and may be associated with the use
of antithrombotic (i.e. anticoagulant or antiplatelet) drugs. The
age-specific incidence of ICH - like the age-specific incidence of
ischaemic stroke and myocardial infarction - rises with age (Feigin
2015). Two-thirds of people who have an ICH are 75 years or
older (Lovelock 2007; Samarasekera 2015). Given that the num-
ber of people aged 75 years and older is projected to rise in many
parts of the world, the burden due to ICH incidence, recurrence,
and prevalence will rise.
Outcome after stroke due to ICH is poor: one-year survival is 46%
(95% confidence interval (CI) 43% to 49%), five-year survival is
29% (95% CI 26% to 33%), and predictors most consistently as-
sociated with death are increasing age, decreasing Glasgow Coma
Scale score, increasing ICH volume, presence of intraventricu-
lar haemorrhage, and deep or infratentorial ICH location (Poon
2014). Approximately one-third of acute ICHs (i.e. less than 24
hours after symptom onset or time last seen well) enlarge from
three to 24 hours after onset (Brott 1997); ICH growth is inde-
pendently associated with death and poor outcome (Davis 2006).
Description of the intervention
The threemain components of haemostasis (the process that stops
bleeding) are vasoconstriction, platelet plug formation, and coag-
ulation.
Vascular smooth muscle cell vasoconstriction is a blood vessel’s
first response to injury. They constrict the damaged vessels, which
reduces the amount of blood flow through the area and limits the
amount of blood loss. Collagen is exposed at the site of injury,
which causes platelets to adhere to the injury site.
Primary haemostasis is achieved by platelets, which adhere to dam-
aged endothelium to form a platelet plug. Plug formation is ac-
tivated by the Von Willebrand factor, which is found in plasma.
When platelets are activated, they express glycoprotein receptors
that interact with other platelets, producing aggregation and ad-
hesion. Platelets release cytoplasmic granules that contain sero-
tonin, adenosine diphosphate (ADP), and thromboxane A2, all of
which increase the effect of vasoconstriction. ADP attracts more
platelets to the affected area, serotonin is a vasoconstrictor, and
thromboxane A2 assists in platelet aggregation, vasoconstriction,
and degranulation.
Secondary haemostasis starts once a platelet plug has been formed.
Blood plasma clotting factors are activated in a sequence of events
known as the coagulation cascade. Inactive fibrinogen produces a
fibrin mesh around the platelet plug to hold it in place. Red and
white blood cells are trapped in the mesh to produce a thrombus,
or clot. Tissue factor (also called platelet tissue factor, factor III,
or thromboplastin) is a protein that is exposed after endothelial
damage, which leads to thrombin formation and activation of the
tissue factor pathway, as well as its circulating ligand factor VII.
Therapies that intervene in primary haemostasis (e.g. platelet
transfusion) or secondary haemostasis (e.g. administration of clot-
ting factors (fresh frozen plasma (FFP), or prothrombin complex
concentrate (PCC), or antifibrinolytic drugs) might promote clot
formation, decrease bleeding, and thus improve outcomes by lim-
iting ICH growth.
How the intervention might work
Theoretically, early interventions to reduce acute ICH volume
might improve outcomes. Although surgical craniotomy to evac-
uate spontaneous supratentorial ICH and reduce ICH volume
was found to reduce the odds of dying or becoming dependent
compared with medical management alone, the result was not
very robust, and surgical evacuation is not frequently used (Prasad
2008). Therefore, medical (non-surgical) interventions to pro-
mote haemostasis, and limit haematoma growth, have become the
main focus of acute ICH therapeutic research.
Why it is important to do this review
Various haemostatic therapies have been investigated in a variety
of spontaneous bleeding conditions with little evidence for their
effectiveness in some settings (Johansen 2015: Stanworth 2012;
Wikkelsø 2013), but clear benefit in others (Ker 2015). It is un-
clear whether they are effective for acute ICH. Therefore, we sys-
tematically reviewed the literature for randomised controlled trials
(RCTs) of all potential haemostatic therapies for the treatment of
acute spontaneous ICH.
O B J E C T I V E S
To examine 1) the effectiveness and safety of individual classes
of haemostatic therapies, compared against placebo or open con-
trol, in adults with acute spontaneous intracerebral haemorrhage
(ICH), and 2) the effects of each class of haemostatic therapy ac-
cording to the type of antithrombotic drug taken immediately be-
fore ICH onset (i.e. anticoagulant, antiplatelet, or none).
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials, whether published or unpublished,
regardless of the language of publication. Pseudo-randomised
studies were not eligible.
Types of participants
People of any sex, aged 16 years or older. We restricted this re-
view topeoplewith radiographically-confirmed acute spontaneous
intracerebral haemorrhage (ICH). Where possible, we grouped
RCTs, or participant subgroups, by whether ICH was associated
with antiplatelet drug use, anticoagulant drug use, or neither.
Types of interventions
Single or multiple haemostatic therapies (including antifibri-
nolytic drugs, blood coagulation factors, antidotes to specific an-
tithrombotic drugs, platelet transfusion, or other platelet activa-
tion therapies), regardless of dosage or route of administration.
Interventions could be compared against placebo, open control,
or an active comparator.
Types of outcome measures
We assessed the following outcomes at 90 days after randomization
(or at the end of scheduled follow-up, if not provided at 90 days).
Primary outcomes
• Death or dependence from any cause (measured on a
standard rating scale, such as the modified Rankin Scale)
Secondary outcomes
• All serious adverse events (if possible, with a separate
analysis of arterial and venous thromboembolic events, including
deep vein thrombosis symptomatic pulmonary embolism,
arterial embolism, myocardial infarction, ischaemic stroke, and
disseminated intravascular coagulation)
• Change in volume of ICH on follow-up brain imaging
• Death from any cause (categorised into early (e.g. less than
seven days) and late (e.g. between seven days and the end of
follow-up) if possible)
• Quality of life
• Mood
• Cognitive function
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module. We searched for trials in all languages, and arranged for
the translation of relevant articles when necessary.
Electronic searches
The Cochrane Stroke Group Information Specialist searched the
Cochrane Stroke Group Trials Register (last searched 27 Novem-
ber 2017), the Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 11) in the Cochrane Library (searched
27 November 2017; Appendix 1); MEDLINE Ovid (1946 to 27
November 2017; Appendix 2); and Embase Ovid (1974 to 27
November 2017; Appendix 3).
One review author (ZL) also searched the following international
registers of RCTs on 27 November 2017.
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (clinicaltrials.gov) using the search strategy in
Appendix 4;
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP; apps.who.int/trialsearch) using
the search strategy in Appendix 5.
Searching other resources
In an effort to identify further published, ongoing, and unpub-
lished RCTs, three authors (RA-SS, NS, and ZL) scanned bibli-
ographies of relevant articles.
Data collection and analysis
Selection of studies
Two authors independently checked the titles and abstracts of
studies identified by the search strategy for RCTs meeting the
selection criteria for the first version of this review (You 2006). Two
authors (ZL or RA-SS) independently screened the results of the
updated searches for potentially eligible studies for this updated
review, and obtained the full published articles or trial registry
entries for studies likely to be relevant RCTs. Two authors (NS and
RA-SS) independently read these potentially eligible RCTs in full,
and confirmed their inclusion according to the inclusion criteria.
Data extraction and management
Two authors (NS and RA-SS) used a standard data collection form
to independently extract data on risk of bias, other RCT charac-
teristics, participants, methods, interventions, outcomes, and re-
sults. If necessary, we sought additional data from the principal
investigators of RCTs that met, or potentially met the inclusion
criteria. We sought unpublished data that were not quantified in
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the original publications, or not presented as stratified by intracra-
nial haemorrhage type, from the principal investigators and phar-
maceutical companies. In the one study for which these data were
not forthcoming, RA-SS measured the numbers in the relevant
groups in the stacked bar charts, using Adobe Acrobat Professional
measuring tools on the PDF of the published study (Mayer 2008
(FAST)). In one phase II study, we could obtain only limited data
from the Novo Nordisk website (F7ICH-1602 2007).
Assessment of risk of bias in included studies
Two authors (NS and RA-SS) independently assessed included
RCTs’ risk of bias, according to the seven criteria of the Cochrane
’Risk of bias’ tool (Higgins 2011). The same two authors discussed
and agreed on the overall quality of the evidence for each outcome,
using the GRADE approach (Higgins 2011).
Measures of treatment effect
We calculated risk ratio (RR) for dichotomous data, and mean
difference (MD), or standardized mean difference (SMD) for dif-
ferent measures of the same outcome, for continuous data.
Dealing with missing data
We sought missing data from studies’ corresponding authors, and
used all the data that were available to us.
Assessment of heterogeneity
We estimated inconsistency between RCTs using the I² statistic.
Assessment of reporting biases
We used funnel plots to assess publication bias where there were
sufficient data.
Data synthesis
We used a random-effects model (because we expected studies of
different drugs and doses to estimate different, yet related, treat-
ment effects) to calculate RRs and 95% confidence intervals (CIs),
with the inverse variance method.
Subgroup analysis and investigation of heterogeneity
We expected to find that the choice of intervention and com-
parator would be largely determined by the use and type of an-
tithrombotic drug taken prior to a spontaneous acute ICH (e.g.
fresh frozen plasma (FFP), or prothrombin complex concentrate
(PCC) for anticoagulant-associated ICH, platelet transfusion for
antiplatelet-associated ICH). However, where interventions were
used for ICH, whether it was associated with antithrombotic drug
use or not (e.g. the clotting factor recombinant activated factor
VII, antifibrinolytic drugs), andwhere ICHevacuationusing cran-
iotomy was performed, we stratified our analyses by pre-ICH an-
tithrombotic drug use and use of surgery.
R E S U L T S
Description of studies
Results of the search
Our searches identified 31 potentially eligible randomised con-
trolled trials (RCT); see Figure 1 for the flowchart describ-
ing the searches done for this update. We excluded nine stud-
ies because: they never started (Ciccone 2007; NCT02429453),
they did not report any of our primary or secondary outcomes
(Meng 2003; Zhou 2005), they did not report data and out-
comes in the intracerebral haemorrhage population (Kerebel
2013; Steiner 2016 (INCH)), they did not quantify outcomes
(Madjdinasab 2008), the study was stopped due to poor enrol-
ment but never reported results (NCT00222625), or the study
did not relate to a haemostatic therapy (Li 2016). Ten RCTs
were still in the process of recruitment (Liu 2017 (TRAIGE);
Meretoja 2014 (STOP-AUST);NCT00699621;NCT02777424;
NCT02866838; NCT03044184; NOR-ICH), follow-up (Sprigg
2016 (TICH-2)), or reporting (NCT00810888; NCT01359202)
at the time of writing, and will be assessed for inclusion with
the next update. This left 12 RCTs that we included in this re-
view, all of which included acute intracerebral haemorrhage (ICH)
in adults aged 18 years or older (Arumugam 2015; Baharoglu
2016 (PATCH); Boulis 1999; F7ICH-1602 2007; Imbert 2012
(PRE-SICH); Li 2012; Mayer 2005a; Mayer 2005b; Mayer
2006; Mayer 2008 (FAST); Sprigg 2014 (TICH-1); Zazulia 2001
(ATICH)).
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Figure 1. Study flow diagram
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We included seven RCTs of blood clotting factors versus placebo
or open control involving 1480 participants (F7ICH-1602 2007;
Imbert 2012 (PRE-SICH); Li 2012; Mayer 2005a; Mayer 2005b;
Mayer 2006; Mayer 2008 (FAST)), three RCTs of antifibri-
nolytic drugs versus placebo or open control involving 57 partic-
ipants (Arumugam 2015; Sprigg 2014 (TICH-1); Zazulia 2001
(ATICH)), one RCT of platelet transfusion versus open control
involving 190 participants (Baharoglu 2016 (PATCH)), and one
RCT of blood clotting factors versus fresh frozen plasma involving
five participants (Boulis 1999).
Included studies
We included 12 RCTs. For details, please refer to the ’
Characteristics of included studies’ table.
Of the seven RCTs of blood clotting factors versus placebo or
open control, six examined blood clotting factors in adults with
acute spontaneous ICH (F7ICH-1602 2007; Li 2012; Mayer
2005a;Mayer 2005b;Mayer 2006;Mayer 2008 (FAST)), and one
in adults with acute spontaneous ICH undergoing craniotomy
(Imbert 2012 (PRE-SICH)). Five studies were funded and con-
ducted by Novo Nordisk, and compared the use of various doses
of intravenous recombinant activated clotting factor VII (rFVIIa;
(973 participants)) against placebo (422 participants), started
within four hours of ICH onset in adults (F7ICH-1602 2007;
Mayer 2005a; Mayer 2005b; Mayer 2006; Mayer 2008 (FAST)).
Novo Nordisk supplied supplementary, unpublished data from
three trials (Mayer 2005a;Mayer 2005b;Mayer 2006), but did not
respond to several requests to provide further data from two trials
(F7ICH-1602 2007;Mayer 2008 (FAST)). The other study of in-
travenous rFVIIa was performed independently of Novo Nordisk,
as a single centre, phase II study, in adults with acute spontaneous
ICH within six hours of ICH onset (Li 2012). We had not pre-
specified the exclusion of RCTs of haemostatic therapies following
surgical intervention, so we included Imbert 2012 (PRE-SICH),
which was a phase II study of intravenous rFVIIa in adults with
acute spontaneous ICHundergoing craniotomy, administered im-
mediately after the evacuation of the haematoma, within 24 hours
of ICH onset.
Of the three RCTs of antifibrinolytic drugs versus placebo or open
control, Zazulia 2001 (ATICH)was a phase II RCTof intravenous
aminocaproic acid compared against supportive treatment alone,
startedwithin three hours of ICHonset in adults.DrAllysonZazu-
lia provided unpublished data, because the trial was stopped after
the enrolment of three participants because recruitment had been
slow, and the investigators decided that the rationale for rFVIIa
was better (Zazulia 2005). Sprigg 2014 (TICH-1) was a phase II
RCT of intravenous tranexamic acid compared against supportive
treatment alone, started within 24 hours of ICH onset in adults.
Arumugam 2015 was a phase II RCT of intravenous tranexamic
acid compared against supportive treatment alone, started within
eight hours of ICH onset in adults.
We found one RCT of platelet transfusion versus open control
involving 190 participants (Baharoglu 2016 (PATCH)).
We found one RCT of blood clotting factors versus fresh frozen
plasma involving five participants with acute spontaneous ICH
associated with anticoagulant drug use (Boulis 1999).
Excluded studies
We excluded nine studies. For details, please refer to the ’
Characteristics of excluded studies’ table. We excluded two eligi-
ble RCTs because they presented aggregate data for adults with
ICH as well as other types of intracranial haemorrhage, and the
study authors could not provide data restricted to the ICH group
alone by the time this review was submitted (Kerebel 2013; Steiner
2016 (INCH)). One abstract proposed a RCT of tranexamic acid
for ICH, but the corresponding author confirmed that funding
had not been obtained (Ciccone 2007). We found two studies of
aprotinin, but it was unclear whether they included some partic-
ipants in both studies, and the outcome measures used were un-
suitable for meta-analysis in this review (Meng 2003; Zhou 2005).
NCT02429453 was a planned RCT of fresh frozen plasma (FFP)
versus prothrombin complex concentrate (PCC), but was termi-
nated before enrolment began. NCT00222625 was a study of co-
agulation factors, but it was “stopped due to slow recruitment”
(Iorio 2012). Dr Iorio has not responded to requests for clarifi-
cation about whether any data were collected. Madjdinasab 2008
was a study of coagulation factors, but no results were reported,
and there was no response from the authors to requests for infor-
mation for this review. Finally, Li 2016 was excluded as the inter-
vention (TRABC) did not appear to be haemostatic, and had four
Traditional Chinese Medicine (TCM) medicinals.
We identified 10 ongoing or recently completed but unreported
RCTs. See ’Characteristics of ongoing studies’ table for details.
Two RCTs examined blood clotting factors versus placebo or open
control (NCT00810888; NCT01359202), five examined antifib-
rinolytic drugs versus placebo or open control in acute sponta-
neous ICH (Liu 2017 (TRAIGE);Meretoja 2014 (STOP-AUST);
NCT03044184; NOR-ICH; Sprigg 2016 (TICH-2)); one RCT
examined antifibrinolytic drugs versus placebo or open control in
acute spontaneous ICH associated with anticoagulant drug use
(NCT02866838); one RCT examined platelet transfusion versus
open control (NCT00699621), and one RCT examined blood
clotting factors versus fresh frozen plasma in acute spontaneous
ICH associated with anticoagulant drug use (NCT02777424).
Risk of bias in included studies
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Across all seven domains in the 12 included RCTs, we assessed
that the risk of bias, according to the Cochrane ’Risk of bias’ tool,
and guidance in the Cochrane Handbook for Systematic Reviews of
Interventions,was unclear in 37 (44%), high in 16 (19%), and low
in 31 (37%; (Figure 2; Figure 3; Higgins 2011)). Only one RCT
was at low risk of bias in all domains (Sprigg 2014 (TICH-1)).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias criteria for each
included study
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias criteria presented as
percentages across all included studies
Allocation
The risk of bias in random sequence generation was low in two
RCTs, unclear in 10 RCTs, and high in none. The risk of bias
in allocation concealment was low in two RCTs, unclear in nine
RCTs, and high in one.
Only four RCTs clearly described the method of randomization (
Baharoglu 2016 (PATCH);Mayer 2005b; Sprigg 2014 (TICH-1);
Zazulia 2001 (ATICH)), and one RCT simply mentioned ’block
randomization according to site’ (Mayer 2008 (FAST)).
Allocation was reported as being concealed in the papers for
Baharoglu 2016 (PATCH) and Sprigg 2014 (TICH-1), there was
a risk of unblinding in one study (Mayer 2008 (FAST)), and the
rest were unclear about allocation concealment.
It became apparent during questioning after the presentation of
the Mayer 2008 (FAST) data at the European Stroke Conference
in Glasgow, UK, in 2007 (Mayer 2007), that the imbalance in
allocation between the three groups in this trial (there were ap-
proximately 30 more participants analysed in the 80 mcg/kg dose
group than the other two groups) was due to the 80 mcg/kg dose
of rFVIIa tending to be packed in the first of the three boxes of
study drug for part of the trial (whichmight have unblinded inves-
tigators, in view of the preponderance of thromboembolic adverse
events with the higher dose).
Blinding
Five of the 12 RCTs did not blind the intervention and compara-
tor (Arumugam 2015; Baharoglu 2016 (PATCH); Boulis 1999;
Imbert 2012 (PRE-SICH); Zazulia 2001 (ATICH)), four did
blind intervention and comparator, and the risk of bias was unclear
in three RCTs. Whether participants and personnel were blinded
to treatment allocation was only explicitly stated in Baharoglu
2016 (PATCH), but correspondence with the study authors veri-
fied that this was the case forMayer 2006; Zazulia 2001 (ATICH),
and Sprigg 2014 (TICH-1). The risk of bias in the remaining
RCTs was unclear in three RCTs, and high in five RCTs.
Risk of bias from blinding of outcome assessment was low in five
RCTs, high in one RCT, and unknown in six RCTs. Assessment of
radiological outcome was blinded to treatment allocation in nine
included RCTs (Arumugam 2015; Baharoglu 2016 (PATCH);
Imbert 2012 (PRE-SICH); Mayer 2005a; Mayer 2005b; Mayer
2006; Mayer 2008 (FAST); Sprigg 2014 (TICH-1); Zazulia 2001
(ATICH)), but information was not provided in others.
Incomplete outcome data
Overall, the risk of bias from incomplete outcome data was low
in six RCTs, high in two RCTs, and unclear in the remaining
four RCTs.Only Baharoglu 2016 (PATCH);Mayer 2008 (FAST),
and Sprigg 2014 (TICH-1) provided data about completeness of
clinical follow-up. In Arumugam 2015 and Li 2012, four partic-
ipants had missing data. Boulis 1999 excluded eight participants
after randomization. The last-observation-carried-forward tech-
nique was used in Mayer 2005b and Mayer 2008 (FAST), which
is likely to be unbiased only if the completeness of follow-up was
high.
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Selective reporting
Bias from selective outcome reporting was low in eight RCTs,
appeared to be low in two RCTs, and high in two other RCTs.
Other potential sources of bias
There were differences in baseline characteristics between treat-
ment and control arms in the rFVIIa RCTs, especially in Mayer
2008 (FAST): 90-day case fatality was worse in the placebo group
inMayer 2005b (29%) than inMayer 2008 (FAST) (19%), which
might be one explanation for the difference between the RCTs’
findings. There was no visual evidence of funnel plot asymmetry in
the largest group of RCTs, which compared blood clotting factors
versus placebo or open control for death or dependency (Figure
4).
Figure 4. Funnel plot of comparison: 1 Blood clotting factors vs placebo or open control, outcome: 1.1
Death or dependence (mRS 4 to 6) at day 90
Effects of interventions
See: Summary of findings for the main comparison Blood
clotting factors versus placebo or open control; Summary of
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findings 2 Antifibrinolytic drugs versus placebo; Summary of
findings 3 Platelet transfusion versus open control; Summary of
findings 4 Blood clotting factors versus fresh frozen plasma
We analysed data on intervention effects In 12 RCTs involving
1732 participants (1150 allocated to intervention and 582 allo-
cated to control or active comparator), split by type of interven-
tion as follows.
Blood clotting factors versus placebo or open control
In RCTs of blood clotting factors (N = 1018) versus placebo or
open control (N = 462) for acute spontaneous ICH with or with-
out surgery, use of blood clotting factors led to non-significant
reductions in death or dependence (risk ratio (RR) 0.87, 95%
confidence interval (CI) 0.70 to 1.07; six trials, 1390 participants;
moderate-quality evidence; Analysis 1.1); in death (RR 0.75, 95%
CI 0.51 to 1.09; seven trials, 1480 participants; moderate-qual-
ity evidence; Analysis 1.3); in all serious adverse events (RR 0.81,
95% CI 0.30 to 2.22; two trials, 87 participants; moderate-qual-
ity evidence; Analysis 1.4); and in ICH growth (RR 0.74, 95%
CI 0.36 to 1.48; three trials, 151 participants; moderate-quality
evidence; Analysis 1.6). Blood clotting factors resulted in a non-
significant increase in all serious thromboembolic serious adverse
events (RR 1.24, 95% CI 0.80 to 1.91; five trials, 1398 partici-
pants; moderate-quality evidence; Analysis 1.5). In these analyses,
the I² varied from 0% to 53%. We downgraded the quality of the
evidence by one level because of concerns with design and risk of
bias.
Antifibrinolytic drugs versus placebo or open control
In RCTs of antifibrinolytic drugs (N = 33) versus placebo or open
control (N = 24) for acute spontaneous ICH, use of antifibri-
nolytic drugs led to non-significant increases in death or depen-
dence (RR 1.25, 95% CI 0.57 to 2.75; one trial, 24 participants;
moderate-quality evidence; Analysis 2.1), in death (RR 1.16, 95%
CI 0.31 to 4.39; three trials, 57 participants; moderate-quality
evidence; Analysis 2.2), in all serious adverse events (RR 1.50,
95% CI 0.39 to 5.83; one trial, 24 participants; moderate-quality
evidence; Analysis 2.3), and in thromboembolic serious adverse
events (RR 1.59, 95%CI 0.07 to 35.15; one trial, 24 participants;
moderate-quality evidence; Analysis 2.4). Antifibrinolytic drugs
led to a non-significant reduction in ICH growth (RR 0.76, 95%
CI 0.56 to 1.05; three trials, 57 participants; moderate-quality
evidence; Analysis 2.7). In these analyses, the I² was 0% to 1%.
We downgraded the quality of the evidence to moderate because
of imprecision.
Platelet transfusion versus open control
In one RCT of platelet transfusion (N = 97) versus open control
(N = 93) for acute spontaneous ICH associated with antiplatelet
drug use, platelet transfusion led to a significant increase in death
or dependence (RR 1.29, 95% CI 1.04 to 1.61; one trial, 190
participants; moderate-quality evidence; Analysis 3.1), and non-
significant increases in death (RR 1.42, 95% CI 0.88 to 2.28; one
trial, 190 participants; moderate-quality evidence; Analysis 3.2),
in all serious adverse events (RR 1.46, 95% CI 0.98 to 2.16; one
trial, 190 participants; moderate-quality evidence; Analysis 3.3),
in thromboembolic serious adverse events (RR 3.84, 95% CI 0.44
to 33.68; one trial, 190 participants; moderate-quality evidence;
Analysis 3.4), and in ICH growth (RR 1.11, 95%CI 0.56 to 2.20;
one trial, 190 participants; moderate-quality evidence; Analysis
3.5). We downgraded the quality of the evidence by one level
because of imprecision.
Clotting factors versus fresh frozen plasma
No conclusions could be drawn from one small RCT of clotting
factors (N = 2) versus fresh frozen plasma (N = 3) for acute spon-
taneous ICH associated with anticoagulant drug use, which did
not report the primary outcome of this review.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Antifibrinolytic drugs compared with placebo for acute spontaneous intracerebral haemorrhage
Patient or population: adults with acute spontaneous intracerebral haemorrhage
Settings: secondary care
Intervention: t ranexamic acid
Comparison: placebo
Outcomes Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Death or dependence (mRS 4 to
6) at day 90
RR 1.25 (0.57 to 2.75) 24
(1)
⊕⊕⊕©
moderate¹
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
CI: conf idence interval; RR: risk rat io; mRS: modif ied Rankin Scale
¹We downgraded the quality of the evidence once because of imprecision.
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Platelet transfusion compared with open control for acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use
Patient or population: adults with acute spontaneous intracerebral haemorrhage associated with ant iplatelet drug use
Settings: secondary care
Intervention: platelet transfusion
Comparison: open control
Outcomes Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Death or dependence (mRS 4 to
6) at day 90
RR 1.29 (1.04 to 1.61) 190
(1)
⊕⊕⊕©
moderate¹
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
CI: conf idence interval; RR: risk rat io; mRS: modif ied Rankin Scale
¹We downgraded the quality of the evidence once because of imprecision.
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Blood clotting factors compared with fresh frozen plasma for acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use
Patient or population: adults with acute spontaneous intracerebral haemorrhage associated with ant icoagulant drug use
Settings: secondary care
Intervention: f resh f rozen plasma (intravenous), vitamin K (subcutaneous), and factor IX complex concentrate
Comparison: f resh f rozen plasma (intravenous)
Outcomes Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Death or dependence (mRS 4 to
6) at day 90
No evidence No evidence as mRS not measured
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
CI: conf idence interval
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D I S C U S S I O N
Summary of main results
There was moderate-quality evidence, based on the findings of one
RCT (190 participants), that platelet transfusion appeared haz-
ardous in comparison to standard care for adults with antiplatelet-
associated intracerebral haemorrhage (ICH). Based on moderate-
quality evidence, we were unable to draw firm conclusions about
the efficacy and safety of blood clotting factors versus placebo or
open control for acute spontaneous ICH with or without surgery
(seven trials, 1480 participants), or antifibrinolytic drugs versus
placebo or open control for acute spontaneous ICH (three tri-
als, 57 participants). The one very small trial (five participants)
we found on clotting factors versus fresh frozen plasma for acute
spontaneous ICH associated with anticoagulant drug use did not
measure our primary outcome, and provided limited data on the
secondary outcomes.
Overall completeness and applicability of
evidence
Alongside the 12 included RCTs, we were unable to include two
eligible RCTs (N = 113) comparing clotting factors versus fresh
frozen plasma for acute spontaneous ICH associated with anti-
coagulant drug use because data on participants with intracere-
bral haemorrhage could not be separated from participants with
subdural intracranial haemorrhage (Kerebel 2013; Steiner 2016
(INCH)). This resulted in a shortage of data comparing clotting
factors versus fresh frozen plasma for acute spontaneous ICH as-
sociated with anticoagulant drug use.
The results of 10 ongoing or recently completed unreported
RCTs are awaiting completion and publication (Characteristics of
ongoing studies). Two of these were recently completed RCTs (N
= 142) investigating clotting factors in participants with radiologi-
cal criteria associated with increased risk of haematoma expansion,
so the RCTs in the review only include all patients with ICH and
not the subgroup most at risk of ICH growth, i.e. those with the
radiological ’spot sign’ (tiny, enhancing foci within haematomas)
(NCT00810888; NCT01359202).
There were few data available on antifibrinolytic drugs versus
placebo after spontaneous acute ICH, but five ongoing RCTs
(N > 2500) are investigating the antifibrinolytic drug tranexamic
acid versus placebo in acute spontaneous ICH without anticoag-
ulant use (Liu 2017 (TRAIGE); Meretoja 2014 (STOP-AUST);
NCT03044184; NOR-ICH; Sprigg 2016 (TICH-2)), and with
anticoagulant drug use (NCT02866838). Publication of the
largest RCT is expected in 2018 (Sprigg 2016 (TICH-2)).
It was unclear whether recruitment was complete for one RCT of
platelet transfusion (N = 100; NCT00699621). Further RCTs of
platelet transfusion seem unlikely, so we await the publication of
this RCT to see if the findings of Baharoglu 2016 (PATCH) are
externally valid.
Quality of the evidence
We included 12 RCTs with 1732 participants (1150 allocated to
intervention, 582 allocated to control or active comparator). One
double-blind RCT (Sprigg 2014 (TICH-1)), and one open RCT
(Baharoglu 2016 (PATCH)), were at low risk of bias, but the risk
of bias of most other RCTs was moderate to high (Figure 2; Figure
3). The RCT finding harm from platelet transfusion has not been
replicated in another RCT (Baharoglu 2016 (PATCH)).
The largest quantity of data was from RCTs of recombinant acti-
vated clotting factor VII (rFVIIa), which were at moderate risk of
bias, and their results were moderately inconsistent, showing non-
significant benefits of rFVIIa. These findings have not changed
practice (Hemphill 2015 (AHA ICH); RCP 2016; Steiner 2014
(ESO ICH)), and have led to explorations of the use of rFVIIa
in ICH sub-groups in as-yet-unpublished RCTs (NCT00810888;
NCT01359202).
We rated the overall quality of all of the available evidence as
moderate for three comparisons on the grounds of imprecision
(Analysis 1.1; Analysis 2.1; Analysis 3.1), and poor for one com-
parison on the grounds of imprecision and limitations in study
design (Analysis 4.1).
Potential biases in the review process
We followed a dual review process: two authors (NS and RA-SS)
independently extracted data that reduced identification bias and
improved risk of bias assessment in comparison to the previous
update of this review.
We were unable to include data from two eligible studies that sep-
arately showed benefits of clotting factors versus FFP on interme-
diate outcomes (speed of international normalised ratio (INR) re-
duction) after intracranial haemorrhage as data were not available
for the ICH population; we hope to include these RCTs in the
next update of this review to also examine the effect of clotting
factors versus FFP on clinical outcomes (Steiner 2016 (INCH);
Kerebel 2013).
Agreements and disagreements with other
studies or reviews
This review was completed after the most recent updates of the
European and North American ICH guidelines (Hemphill 2015
(AHA ICH); Steiner 2014 (ESO ICH)). These guidelines pre-
dated the results of Baharoglu 2016 (PATCH), and simply found
that “the usefulness of platelet transfusions in ICH patients with
a history of antiplatelet use is uncertain”. Guidance on platelet
transfusion has changed to reflect the results of Baharoglu 2016
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(PATCH), where platelet transfusion was associated with a worse
outcome, hence platelet transfusion is not recommended (Dastur
2017). Consistent with our findings, guidelines have not recom-
mended the use of clotting factors, such as rFVIIa for acute sponta-
neous ICH not associated with anticoagulant use (Hemphill 2015
(AHA ICH); RCP 2016; Steiner 2014 (ESO ICH)). The AHA
and ESO guidelines preceded the publication of Steiner 2016
(INCH), but the national stroke guidelines in the UK recommend
using prothrombin complex concentrate for anticoagulant-associ-
ated ICH, reflecting the findings of Steiner 2016 (INCH) on the
intermediate outcome of speed of INR reduction (RCP 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Platelet transfusion appears hazardous in comparison to standard
care for adults with antiplatelet-associated ICH (this is based on
the findings of one trial). We are unable to draw firm conclusions
about the efficacy and safety of blood clotting factors for acute
spontaneous ICH (with or without surgery), antifibrinolytic drugs
for acute spontaneous ICH, clotting factors or fresh frozen plasma
for acute spontaneous ICH associated with anticoagulant drug
use.
Implications for research
Although rFVIIa does not appear beneficial on the basis of
existing evidence, RCTs of its use in specific subgroups have
been undertaken and their results are awaited (NCT00810888;
NCT01359202). Clotting factors appear superior to fresh frozen
plasma for normalising coagulation in the RCTs that we could
not include because they were not restricted to ICH (Kerebel
2013; Steiner 2016 (INCH)), but their superiority for improving
clinical outcome needs to be established. The effect of antifibri-
nolytic drugs for acute ICH is uncertain, but in view of their ef-
fects in other conditions (Ker 2015), the results of several ongoing
RCTs are keenly awaited (Liu 2017 (TRAIGE); Meretoja 2014
(STOP-AUST); NCT02866838; NCT03044184; Sprigg 2016
(TICH-2)).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arumugam 2015
Methods Single-blinded, randomised placebo-controlled trial of tranexamic acid (intravenous 1 g
bolus, followed by infusion 1 g/h for 8 h) in acute (< 8 h) primary ICH. Strict blood
pressure control (target SBP 140 mmHg to 160 mmHg)
A repeat brain CT was done after 24 h to reassess haematoma growth. The primary
objective was to test the effect of tranexamic acid on haematoma growth.Other objectives
were to test the feasibility, tolerability, and adverse events of tranexamic acid in primary
ICH
Participants Inclusion criteria
• Patients aged ≥ 18 years (either sex),
• Non-surgically managed patients who were evaluated by the on-call neurosurgeon
and, were deemed inappropriate for surgical intervention,
• Event within 8 h of onset,
• Hypertensive intracerebral bleed, and
• Supratentorial lesion.
Exclusion criteria
• Patients on anticoagulant therapy,
• Brainstem bleed,
• Intraventricular bleed on the first brain CT brain, including participants who
developed an intraventricular bleed during the study,
• Malignant hypertension,
• Subarachnoid haemorrhage suggestive of a ruptured aneurysm,
• Trauma,
• Blood disorder (e.g. haemophilia and idiopathic thrombocytopenic purpura),
• Infection (e.g. dengue haemorrhagic fever),
• Hepatic or renal impairment,
• Previous venous thrombosis or embolic disease,
• Recent ischaemic event (within 12 months), such as ischaemic stroke, MI, or
peripheral artery disease, and
• Pregnant or breast-feeding women (pregnancy was evaluated in women of child-
bearing age using a urine pregnancy test).
Interventions Intervention: tranexamic acid (1 g diluted in 100 mL of 0.9% saline) over a period of 10
minutes. The initial dose was followed by a maintenance dose of 1 g/h for 8 h. Labetalol
infusion 2 mg/min to achieve SBP 140 mmHg to 160 mmHg
Comparator: placebo mentioned, but not described. Labetalol infusion 2 mg/min to
achieve SBP 140 mmHg to 160 mmHg
Outcomes Repeat CT brain scan was performed after 24 h, and a blinded radiologist evaluated the
size and volume of the haematoma. Adverse events due to tranexamic acid that occurred
within 24 h of the treatment were documented by the investigator or pharmacist
Notes
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Arumugam 2015 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Each envelope represented either
the drug or control group, which was as-
signed using a random sequence program-
mer.”
Allocation concealment (selection bias) Unclear risk Quote: “Patients or their family members
randomly chose one envelope from a box
containing 30 closed envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded radiologist for primary outcome.
High risk for other outcomes (not stated as
blinded)
Incomplete outcome data (attrition bias)
All outcomes
High risk 4 participants had missing data
Selective reporting (reporting bias) Low risk All outcomes in the paper were reported.
No protocol
Baharoglu 2016 (PATCH)
Methods Multicentre, open-label, masked-endpoint, randomized trial, using a secure web-based
system that concealed allocation and used biased coin randomization (1:1 stratified by
hospital and type of antiplatelet therapy)
Participants Inclusion criteria
• Participants aged 18 years or older
• Non-traumatic supratentorial intracerebral haemorrhage confirmed by brain
imaging
• GCS score of 8 to 15
• In whom platelet transfusion could be initiated within 6 h of symptom onset (or
last seen well) and within 90 minutes of brain imaging
• Who had been on antiplatelet therapy with a cyclo-oxygenase (COX) inhibitor
(aspirin or carbasalate calcium), adenosine diphosphate (ADP) receptor inhibitor
(clopidogrel), or an adenosine reuptake inhibitor (dipyridamole) for at least 7 days
preceding intracerebral haemorrhage
• Pre-intracerebral haemorrhage mRS score of 0 (no symptoms) or 1 (no significant
disability despite symptoms; able to carry out all usual duties and activities)
Exclusion criteria
• Blood on brain imaging suggestive of epidural or subdural haematoma, or an
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Baharoglu 2016 (PATCH) (Continued)
underlying aneurysm or arteriovenous malformation
• Planned surgical evacuation of intracerebral haemorrhage within 24 h of
admission
• Intraventricular blood more than sedimentation in the posterior horns of the
lateral ventricles
• Previous adverse reaction to platelet transfusion
• Known use of vitamin K antagonist (unless INR≤ 1.3) or history of coagulopathy
• Known thrombocytopenia (lower than 100 cells x 10
/L)
• Lacking mental capacity by national legal standards before intracerebral
haemorrhage
• Death appeared imminent
Interventions Intervention: standard care with platelet transfusion within 90 minutes of diagnostic
brain imaging
Comparator: standard care
Outcomes The primary outcome was shift towards death or dependence rated on the mRS at 3
months, and analysed by ordinal logistic regression, adjusted for stratification. Variables
and the Intracerebral Haemorrhage Score Secondary clinical outcomes at 3months were:
survival (mRS score of 1 to 5), poor outcome defined as an mRS score of 4 to 6, and
poor outcome defined as an mRS score of 3 to 6
The secondary explanatory outcome was median absolute intracerebral haemorrhage
growth in mL after 24 h on brain imaging
Safety outcomes were defined as complications of platelet transfusion (transfusion reac-
tions, thrombotic complications)
Notes NTR1303
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisationwas done by inves-
tigators via a secure, web-based, comput-
erised randomization system (TENALEA,
Clinical Trial Data Management system;
NKIAVL, Amsterdam, The Netherlands)
that stratified assignment by study hospi-
tal and type of pre-intracerebral haemor-
rhage antiplatelet therapy (COX inhibitor
alone, ADP receptor inhibitor alone, COX
inhibitor with an adenosine-reuptake in-
hibitor, or COX inhibitor with an ADP re-
ceptor inhibitor). A biased coin random-
ization was used, with coin bias factor of 3
and coin bias threshold of 2”
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Baharoglu 2016 (PATCH) (Continued)
Allocation concealment (selection bias) Low risk Allocation was concealed from investiga-
tors by the web-based randomization sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and local investigators giving
interventions were not masked to treat-
ment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Treatment allocation was concealed to out-
come assessors and investigators analysing
data
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for the primary outcome was
complete
Selective reporting (reporting bias) Low risk All outcomes were reported
Boulis 1999
Methods RCT
Participants Inclusion criteria
• CT-proven intracranial haemorrhage
• Documented history of warfarin use
• Prothrombin time > 17 seconds
Exclusion criteria
• Clinical evidence of brainstem herniation
Interventions Intervention: fresh frozen plasma
Comparator: fresh frozen plasma (intravenous), vitamin K (subcutaneous) and factor IX
complex concentrate (Konyne; Bayer, Elkhart, IN: containing high concentrations of
activated vitamin K-dependent clotting factors II, VII, IX, and X; dosage according to
body weight; intravenous infusion at 100 IU/min)
Outcomes Time to INR correction, rate of INR correction, change in GCS
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
Allocation concealment (selection bias) Unclear risk Not mentioned
25Haemostatic therapies for acute spontaneous intracerebral haemorrhage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boulis 1999 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not described
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding was not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Post-randomisation exclusion of 8 participants
Selective reporting (reporting bias) Unclear risk Outcomes not pre-specified
F7ICH-1602 2007
Methods Randomised, double-blind, Japanese multicentre, placebo-controlled, phase II dose-
escalation trial with 3 dose tiers
Participants Inclusion criteria
• Age ≥ 20 years
• Spontaneous ICH (not in brainstem)
• Within 3 h of onset
Interventions Intervention: recombinant activated factor VII (NovoSeven) at doses of 40 mcg/kg (N
= 15), 80 mcg/kg (N = 15), or 120 mcg/kg (N = 15), within 1 h of baseline CT
Comparator: placebo (N = 45), within 1 h of baseline CT
Outcomes Preliminary efficacy evaluations were performed as follows
• mRS, the BI scores at 15 days post-dose and 90 days post-dose
• Absolute and percent change in ICH volume, total haemorrhage volume (ICH +
IVH), and total lesion volumes (ICH + IVH + oedema) as measured by head CT scans
from baseline to 24 h, 48 h, and 72 h post-dose
• Change in the GCS and the NIHSS scores from baseline to 1 h post-dose, 24 h
post-dose, 48 h post-dose, 72 h post-dose, 15 days post-dose, and 90 days post-dose
• Mortality at 90 days post-dose
Criteria for evaluation: safety
• Occurrence of thromboembolic serious adverse events until the ’End of trial’ form
was completed
• Changes in laboratory coagulation parameters (D-dimer, Fragment 1+2,
Fibrinogen, Platelets, PT-INR, and APTT) from prior to dosing to 1 h post-dose, 24 h
post-dose, 48 h post-dose, and 72 h post-dose
• Exacerbation of brain oedema (oedema/ICH volume ratio > 2.5) assessed using
head CT scan at 24 h post-dose, 48 h post-dose, and 72 h post-dose
• Occurrence of adverse events until discharge or 90 days post-dose, whichever
came first, and serious adverse events until the ’End of trial’ form was completed
Notes ClinicalTrials.gov number NCT00266006. This unpublished trial was funded by Novo
Nordisk, which did not respond to requests to provide data beyond what was on their
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F7ICH-1602 2007 (Continued)
website
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants and personnel said to be
blinded to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The assessment of outcomes was not ex-
plicitly stated to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not specified
Selective reporting (reporting bias) High risk Data not provided for most major out-
comes
Imbert 2012 (PRE-SICH)
Methods Randomised (2:1), open-label, single-blinded parallel group phase 2 pilot trial involving
21 participants with spontaneous supratentorial ICH diagnosed by CT
Participants Inclusion criteria
• People 18 to 75 years of age with spontaneous supratentorial ICH documented by
CT scan
• Surgery was expected within 24 h from the onset of symptoms
Exclusion criteria
• MI or the placement of coronary or carotid stents in the 6 months prior to the
study
• Solid organ transplantation
• Pregnancy
Interventions All participants were intubated, ventilated, and underwent craniotomy with the inten-
tion of complete haematoma removal. The haematoma cavity was lined with Surgicel
(Johnson & Johnson, New Brunswick, NJ, USA). Blood pressure was measured contin-
uously, and data were collected every 1 to 2 h. Efforts were made to maintain the mean
arterial blood pressure between 90 mmHg and 130 mmHg, PaCO within the range
of 35 mmHg to 40 mmHg, natraemia between 137 and 147 mmol/L and to obtain
normoglycaemia (80 mg/dL to 110 mg/dL)
Intervention: 100 mcg/kg of rFVIIa (NovoSeven, Novo Nordisk, Denmark) by intra-
venous infusion in 5 to 10 minutes immediately after evacuation of the haematoma, at
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Imbert 2012 (PRE-SICH) (Continued)
the beginning of the closure of the dura
Comparator: saline solution by intravenous infusion in 5 to 10 minutes immediately
after evacuation of the haematoma, at the beginning of the closure of the dura
Outcomes Haematoma volume was assessed by CT scan immediately, 18 h to 30 h, and 5 days to 7
days after evacuation of the haematoma. The primary endpoint was haematoma volume
at 18 h to 30 h after surgery. Outcome was evaluated at 6 months using the mRS; poor
outcome was defined as death or an mRS score of 4 to 5, and good outcome was defined
as an mRS score of 0 to 3
Notes NCT00128050
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk They stated the trial was both open la-
bel and placebo controlled in the methods,
but that ’saline’ was the comparator. This
seemed like an open trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Haematoma volume assessment blinded,
but unsure about clinical outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Seemed complete for all outcomes. Un-
able to extract data on haematoma growth,
all SAEs, and all thromboembolic adverse
events (although they were reported sepa-
rately)
Selective reporting (reporting bias) Low risk All outcomes specified in the methods ap-
peared to have been reported
Li 2012
Methods Single-centre RCT
Participants Inclusion criteria
• Intracerebral haemorrhage
• Within 6 h of onset
• Age ≥ 18 years
• Able to perform CT scan 24 h post-treatment
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Li 2012 (Continued)
Exclusion criteria
• Secondary haemorrhage, i.e. tumour, AVM, anticoagulant-associated
• Surgery within 24 h
• Admission GCS 3 to 5
• Hereditary or acquired coagulation dysfunction
• Previous ICH in which haematoma had not been fully resolved
• Serious comorbidities or end-stage diseases (unspecified)
• Known renal impairment or thyroid dysfunction (unspecified)
Interventions Intervention: intravenous rFVIIa (NovoSeven) 40 µg/kg, concentration at 0.6 g/L,
within 6 h of ICH onset, injected over 2 to 5 minutes
Comparator: routine or best medical treatment
All participants received Piracetam 8 g iv 4 times/day
Outcomes ICH growth, GCS at 24 h, NIHSS at 24 h, mRS at 90 days, adverse events
Notes Data extracted byDrMichael Poon (www.researchgate.net/profile/Michael Poon3) from
full text record available from en.cnki.com.cn/Article en/CJFDTotal-ZXYZ201202009.
htm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not mentioned
Selective reporting (reporting bias) Low risk All outcomes appeared to be reported
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Mayer 2005a
Methods Parallel group, randomised, placebo-controlled, phase II: a dose-escalation safety and
efficacy study
Participants Inclusion criteria:
• Age 18 years or older
• Spontaneous ICH within 3 h of onset with no obvious secondary cause
Exclusion criteria:
• GCS 3 to 5
• Surgical ICH evacuation planned within 24 h
• mRS > 2 pre-ICH
• Allergy to trial product
• Participation in another RCT
Interventions Intervention: recombinant activated factor VII (NovoSeven) at doses of 10 mcg/kg, 20
mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg, or 160 mcg/kg, within 1 h of baseline CT
Comparator: placebo, within 1 h of baseline CT
Outcomes Adverse events at days 1 to 5, 15 (or hospital discharge), and 90; change in ICH ± IVH
volume on CT between baseline and 24 h; ICH growth (> 33% or 12.5 mL); drop of
> 1 GCS point or increase of > 3 NIHSS points on days 0 to 5; dead versus alive with
little disability (BI 95 to 100, GOS-E 8, mRS 0 to 2), versus alive and functionally
independent (BI 60 to 100, GOS-E 5 to 8, mRS 0 to 3) at day 90
Notes There was imbalance in the baseline ICHvolumes between placebo and treatment groups
(increasing with higher recombinant factor VIIa doses), although the authors stated that
this was not statistically significant. The trial drug was given to 2 of 47 participants more
than 4 h after ICH onset. This trial was funded by Novo Nordisk
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of randomization was not
specified
Allocation concealment (selection bias) Unclear risk Not described. Quote: “A randomization
schedule was generated.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Providers were said to be blinded to treat-
ment allocation (but treatment dose esca-
lation may have been apparent)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The assessment of outcomes was not ex-
plicitly stated to be blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear
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Selective reporting (reporting bias) Unclear risk Unclear
Mayer 2005b
Methods Parallel group, randomised, placebo-controlled, phase IIB, dose-ranging, proof-of-con-
cept study
Participants Inclusion criteria:
• Age 18 years or older
• Spontaneous ICH
• Within 3 h of onset
Exclusion criteria:
• GCS 3 to 5
• Surgical ICH evacuation planned within 24 h
• Known underlying cause of ICH
• On oral anticoagulants
• Known thrombocytopaenia
• Coagulopathy, disseminated intravascular coagulation, sepsis, or crush injury
• Pregnant
• mRS > 2 pre-ICH
• Symptomatic thrombotic or vaso-occlusive disease within 30 days before ICH
(mid-way through the trial this was amended to exclude patients with any history of
thrombotic or vaso-occlusive disease)
Interventions Intervention: recombinant activated factor VII (NovoSeven) at doses of 40 mcg/kg, 80
mcg/kg, or 160 mcg/kg, within 1 h of baseline CT and no later than 4 h after ICH onset
Comparator: placebo, within 1 h of baseline CT and no later than 4 h after ICH onset
Outcomes Percentage change in ICH volume on CT from baseline to 24 h; mRS 4 to 6, or GOS-
E 1 to 4 at 90 days; adverse events in hospital, and serious adverse events until day 90
Notes One important exclusion criterion was changed mid-way through the RCT. This trial
was funded by Novo Nordisk, which did not respond to repeated requests to provide
further data from this trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Quote: “A randomization schedule was
generated and as patients were recruited,
they were allocated to the next available
randomization number within the dose
tier, which indicated whether the patient
was to receive placebo or rFVIIa.”
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Mayer 2005b (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk 4/block, sequentially numbered, identical-
appearing containers
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Radiological outcomes blinded. Clinical
and lab outcomes - unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appeared complete
Selective reporting (reporting bias) Low risk Appeared complete
Mayer 2006
Methods Parallel group, randomised, double-blind, placebo-controlled, phase II: a dose escalation
safety study
Participants Inclusion criteria
• Age 18 years or older
• Spontaneous ICH within 3 h of onset
Exclusion criteria
• GCS 3 to 5
• Surgical ICH evacuation planned within 24 h
• Known underlying cause of ICH
• On oral anticoagulants
• Known thrombocytopaenia
• Coagulopathy, disseminated intravascular coagulation, sepsis, or crush injury
• Pregnant
• mRS > 2 pre-ICH
• Any history or acute evidence of thrombotic, hypercoagulable, or vaso-occlusive
disease
• Known or suspected allergy to trial product
• Participation in another trial
Interventions Intervention: recombinant activated factor VII (NovoSeven) at doses of 5 mcg/kg, 20
mcg/kg, 40 mcg/kg, or 80 mcg/kg, within 4 h of ICH onset
Comparator: placebo, within 4 h of ICH onset
Outcomes Serious adverse events; coagulation parameters; perihaematomal oedema; ICH volume
ratio on CT; change in ICH volume from baseline on CT; change in neurological scores
Notes This trial was funded by Novo Nordisk
Risk of bias
Bias Authors’ judgement Support for judgement
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Mayer 2006 (Continued)
Random sequence generation (selection
bias)
Unclear risk The method of randomization was not de-
scribed
Allocation concealment (selection bias) Unclear risk Themethod of allocation concealment was
not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 participant clinically deteriorated prior
to dosing and underwent emergency
haematoma evacuation, so dropped out af-
ter randomization. Otherwise, complete-
ness of follow-up was not mentioned
Selective reporting (reporting bias) Low risk All stated outcomes were reported
Mayer 2008 (FAST)
Methods Parallel group, randomised, placebo-controlled, phase III trial
Participants Inclusion criteria
• Spontaneous ICH (including bleeding in brainstem and cerebellum) diagnosed by
a CT scan within 3 h of symptom onset
• Men or women, aged 18 years or over (20 or over in Taiwan)
• Informed consent
Exclusion criteria
• Time of ICH onset is unknown, or more than 3 h
• People with secondary ICH
• Surgical haematoma evacuation planned within 24 h of symptom onset
• GCS 3 to 5
• Known oral anticoagulant use (unless the INR is documented below 1.4)
• Known thrombocytopenia (unless current platelets documented above 50,000/
mL)
• Pre-existing disability (mRS 3 to 5)
• Any known history of haemophilia or other coagulopathy
• Known acute myocardial ischaemia, unresolved unstable angina, acute
septicaemia, acute crush injury, acute disseminated intravascular coagulation, or acute
thrombotic stroke
• Pregnancy
• Known or suspected allergy to trial product or related products
• Previous participation in this trial
• Known participation in any investigational drug or device trial within 30 days of
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entry into this trial
• People known or suspected of not being able to comply with this trial protocol (e.
g. due to alcoholism, drug dependency, or psychological disorder)
Interventions Intervention:
Recombinant activated factor VII (NovoSeven) at doses of 20 mcg/kg or 80 mcg/kg,
within 1 h of baseline CT and no later than 4 h after ICH onset
Comparator:
Placebo
Outcomes Primary efficacy endpoint was poor outcome, defined as death or severe disability (scores
of 5 to 6 on the mRS) at day 90. Analysis claimed to be intention-to-treat, but it did
not appear to be
Secondary efficacy endpoints: BI, GOS-E, NIHSS, the EuroQol scale, and the Revised
Hamilton Rating Scale for Depression at day 90; absolute and percent change in ICH
volume as measured by CT from prior to dosing to 24 h after the baseline scan; good
outcome (mRS 0 to 1) at day 90; absolute and percent change in total lesion volumes
(ICH + IVH + oedema) from baseline to 72 h; BI at day 90; case fatality
Safety endpoints: the occurrence of adverse events until hospital discharge, or until day
90, whichever came first, and serious adverse events until the ’End of trial’ form was
completed
Notes This trial was funded by Novo Nordisk, which did not respond to repeated requests to
provide further data from this trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Block randomization according to
site...”
Allocation concealment (selection bias) High risk It became apparent during questioning af-
ter the presentation of this trial’s data at
the European Stroke Conference (Glasgow
2007), that the imbalance in allocation be-
tween the 3 groups in this trial (there were
approximately 30 more participants anal-
ysed in the 80 mcg/kg dose group than the
other 2 groups) was due to the fact that
the 80 mcg/kg dose of rFVIIa tended to
be packed in the first of the 3 boxes of
study drug for part of the trial (whichmight
have unblinded investigators, in view of the
preponderance of thromboembolic adverse
events with the higher dose)
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Mayer 2008 (FAST) (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Classified as ’double-blind’, but not de-
scribed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Classified as ’double-blind’, but not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Outcome scores at day 15 were
used according to the principle of the last
observation carried forward for 9 patients
receiving placebo, 9 patients receiving 20
µg of rFVIIa per kilogram, and 13 patients
receiving 80 µg of rFVIIa per kilogram (3.
7% of patients overall), for whom scores
at day 90 were missing. Modified Rankin
scale scores were not available for one pa-
tient receiving placebo and one patient re-
ceiving 20 µg of rFVIIa per kilogram.”
Selective reporting (reporting bias) High risk EuroQuol and Hamilton depression score
not reported
Sprigg 2014 (TICH-1)
Methods Single-centre, prospective, randomised (2:1), double-blind, placebo-controlled blinded
endpoint trial of tranexamic acid (intravenous 1 g bolus, 1 g infusion/8 h) in acute (<
24 h) spontaneous ICH
Participants Adults with acute (< 24 h after ictus) spontaneous ICH were identified and enrolled
from the stroke service at Nottingham University Hospital NHS Trust. The principal
exclusion criteria included secondary ICH (anticoagulation, known vascular malforma-
tions), previous venous thromboembolic disease, recent (< 12 months) ischaemic events
(ischaemic stroke, MI, PAD), renal impairment (estimated glomerular filtration rate <
50 mmol), and pregnancy or breast feeding
Interventions Intervention: intravenous tranexamic acid (Cyklokapron; Phamacia Limited, Kent, UK)
administered as a 1 g loading dose infusion for 10 minutes followed by a 1 g infusion
for a period of 8 h
Comparator: matching placebo (0.9% saline) administered by identical regime
Outcomes The primary outcome was trial feasibility (surrogate for trial acceptability: number of
participants screened who were eligible for enrolment and who gave informed consent)
Secondary outcomes included tolerability (adverse events occurring during or after ad-
ministration of tranexamic acid) and safety (clinical information on ischaemic events, i.
e. ischaemic stroke, TIA, acute coronary syndrome, PAD, and VTE were also recorded)
. The Data Safety Monitoring Committee reviewed unblinded safety data after 6, 12,
and 18 participants had been recruited and followed for 7 days
35Haemostatic therapies for acute spontaneous intracerebral haemorrhage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sprigg 2014 (TICH-1) (Continued)
Notes Dr N Sprigg provided information for assessment of risk of bias
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Details not given in paper, but confirmed
by author as computer-generated
Allocation concealment (selection bias) Low risk Details not given in paper, but confirmed
by author as concealment until end of trial
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Details not given in paper, but confirmed
by author as participants and trial staff all
blinded to allocation for duration of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not presented in paper, but author con-
firmed all assessments (clinical and radio-
logical) were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data presented
Selective reporting (reporting bias) Low risk No selective reporting
Zazulia 2001 (ATICH)
Methods Parallel group, RCT
Participants Inclusion criteria:
• spontaneous non-traumatic supratentorial ICH (on brain CT),
• age 18 years or older,
• treatment begun within 3 h of ICH onset
Exclusion criteria:
• clinical suspicion of ICH due to aneurysm, tumour, bleeding diathesis,
• SAH Fisher grade > 3,
• plans for immediate surgery,
• on coumadin,
• prothrombin time > 14,
• pregnant,
• platelet count < 100,000,
• undergoing haemodialysis,
• treated with thrombolytic therapy in the last 48 h,
• known DVT, MI, or PE within the last 3 months,
• acute MI on ECG,
• GCS < 5
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Interventions Intervention: aminocaproic acid (Amicar) intravenous bolus of 10 g over 5 to 10minutes,
followed by a continuous intravenous infusion of 50 g diluted in 478 mL 0.9% NaCl
and infused at 30 cc/h over 24 h
Comparator: routine treatment
Outcomes • Antifibrinolytic activity levels,
• ICH enlargement on CT by > 33% from baseline to 24 h,
• in-hospital death,
• 90-day case fatality,
• FIM and mRS,
• aminocaproic acid plasma levels,
• development of ischaemic stroke (defined as a new lucency in a vascular
distribution not in the area of the initial haemorrhage on the 7-day CT, or a new focal
neurological deficit reflecting a vascular territory separate from the initial haemorrhage
and that cannot be explained by other cause),
• symptomatic DVT confirmed by venous duplex ultrasonography,
• symptomatic PE confirmed by ventilation-perfusion lung scan, pulmonary
angiogram, or autopsy,
• change in hydrocephalus score,
• laboratory evidence of disseminated intravascular coagulation,
• evidence of haemodynamic compromise during drug infusion (hypotension >
15% of baseline mean arterial pressure ± bradycardia or arrhythmia)
Notes Studied terminated prematurely after 3 participants enrolled
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 10/block
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Radiological outcomes blinded. Clinical outcomes unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete data presented
Selective reporting (reporting bias) Low risk No selective reporting
APTT: activated partial thromboplastin time
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AVM: arteriovenous malformation
BI: Barthel Index
CT: computed tomography
DVT: deep vein thrombosis
ECG: electrocardiogram
FIM: Functional Independence Measure
GCS: Glasgow Coma Score
GOS-E: Extended Glasgow Outcome Scale
ICH: intracerebral haemorrhage
INR: international normalised ratio
IVH: intraventricular haemorrhage
MI: myocardial infarction
mRS: modified Rankin Scale
NaCl: sodium chloride
NIHSS: National Institutes of Health Stroke Scale
PE: pulmonary embolism
RCT: randomised controlled trial
SAE: serious adverse event
SAH: subarachnoid haemorrhage
SBP: systolic blood pressure
TIA: transient ischaemic attack
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ciccone 2007 This was a proposal for a study, but was not initiated due to ’lack of funding’, according to Dr Ciccone
Kerebel 2013 This trial combined participants with either intracerebral haemorrhage or subdural haemorrhage, but did
not report outcomes by intracranial haemorrhage subtype. We requested data restricted to the group with
ICH, but did not receive these data before submission of this review; we hope to include them in the next
update
Li 2016 The intervention (TRABC) did not appear to be haemostatic, according to a Traditional Chinese Medicine
expert (sarah-price.co.uk/): Xing Nao Jing has 4 TCMmedicinals (She Xiang, Yu Jin, Zhi Zi and Bing Pian)
, traditionally used to revive the unconscious patient
Madjdinasab 2008 No quantifiable outcome results were reported.
Meng 2003 It was unclear whether the participants in this studywere included inZhou 2005. The outcomemeasures used
were unsuitable for meta-analysis in this review. none of the pre-specified primary or secondary outcomes
were collected
NCT00222625 This study was ’stopped due to slow recruitment’, according to Dr Iorio, who has not yet responded to
requests for clarification about whether any data were collected
NCT02429453 This study was ’withdrawn before enrolment’, according to the Clinical Trial Registry
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Steiner 2016 (INCH) This trial combined participants with either intracerebral haemorrhage or subdural haemorrhage, but did
not report outcomes by intracranial haemorrhage subtype. We requested data restricted to the group with
ICH, but did not receive these data before submission of this review; we hope to include them in the next
update
Zhou 2005 It was unclear whether this study included the participants in Meng 2003. The outcome measures used were
unsuitable for meta-analysis in this review, none of the pre-specified primary or secondary outcomes were
collected
ICH: intracerebral haemorrhage
Characteristics of ongoing studies [ordered by study ID]
Liu 2017 (TRAIGE)
Trial name or title Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign (TRAIGE)
Methods The purpose of this study is to determine if CTA can predict which individuals with ICH will experience
significant growth in the size of the haemorrhage. For individuals who are at high risk for haemorrhage growth,
the study will compare the drug tranexamic acid to placebo to determine the effect and safety on ICH
Participants Inclusion criteria
People presenting with an acute spontaneous hypertensive ICH
• CTA evaluation can be accomplished within 6 h of symptom onset, with ’spot sign’ positive in CTA
original image
• Age range from 18 to 79 years
• Randomisation can be finished and treatment can commence within 8 h of symptom onset
• Informed consent has been received in accordance with local ethics committee requirements
Exclusion Criteria:
• ICH known or suspected to be secondary to tumour, vascular malformation, aneurysm, or trauma
• Infratentorial ICH
• GCS total score < 8
• ICH volume > 70 mL
• Parenchymal haemorrhage with ventricle involved, blood completely fills one lateral ventricle or more
than half of both lateral ventricles
• Contraindication of CTA imaging (e.g. known or suspected iodine allergy or significant renal failure)
• Any history or current evidence suggestive of venous or arterial thrombotic events within the previous
6 months, including clinical, ECG, laboratory, or imaging findings. Clinically silent chance findings of old
ischaemia are not considered exclusion criteria.
• Planned surgery for ICH
• Pregnancy, within 30 days after delivery, or during lactation
• Use of heparin, low-molecular weight heparin, or oral anticoagulation within the previous 1 week,
with abnormal laboratory values
• Known allergy to tranexamic acid
• Prestroke modified mRS score of > 2
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Interventions Intervention: tranexamic acid
Comparator: 0.9% normal saline placebo
Outcomes Primary outcome measures
• haemorrhage growth (time frame: 24 ± 2 h) either > 33%, or > 6 mL increase from baseline, adjusted
for baseline ICH volume
Secondary outcome measures
• Major thromboembolic events (time frame: 30 ± 4 days; acute MI, acute cerebral ischaemia, acute PE)
• Poor clinical outcome (time frame: 90 ± 7 days): the number of participants who died or have major
disability (mRS 4 to 6)
• Short-term outcome: the number of participants with mRS 0 to 2 at 30 ± 4 days
• Other thromboembolic events (time frame: 90 ± 7 days): other thromboembolic events, such as venous
thrombosis and other peripheral arterial embolism
• Death due to any cause: number of patients that died due to any cause by 90 ± 7 days
Starting date September 2015
Contact information Liping Liu, Professor of Neurology and Stroke Center, Beijing Tiantan Hospital, Capital Medical University,
Ministry of Science and Technology of the People’s Republic of China
Notes NCT02625948
Meretoja 2014 (STOP-AUST)
Trial name or title STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial (STOP-
AUST)
Methods The aim of the study is to test if ICH patients who have contrast extravasation on CTA, the ’spot sign’, have
lower rates of haematoma growth when treated with tranexamic acid within 4.5 h of stroke onset, compared
with placebo
Participants Inclusion criteria
• People presenting with an acute ICH
• Contrast extravasation within the haemorrhage, ’spot sign’, evaluated from the CTA according to 3
criteria, all of which must be present: Serpiginous or spot-like appearance within the margin of a
parenchymal haematoma without connection to an outside vessel; the density (in Hounsfield units) should
be greater than that of the background haematoma (site investigators are not required to document the
density); and no hyperdensity at the corresponding location on non-contrast CT
• Age ≥ 18 years
• Treatment can commence within 1 h of initial CT and within 4.5 h of symptom onset (or in people
with unknown time of symptom onset, the time the person was last known to be well)
• Informed consent has been received in accordance to local ethics committee requirements
Exclusion criteria
• GCS total score < 8
• Brainstem ICH
• ICH volume > 70 mL as measured by the ABC/2 method
• ICH known or suspected by study investigator to be secondary to trauma, aneurysm, vascular
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malformation, haemorrhagic transformation of ischaemic stroke, cerebral venous thrombosis, thrombolytic
therapy, tumour, or infection
• Contrast already administered within 24 h prior to initial CT or contraindication to imaging with CT
contrast agents (e.g. known or suspected iodine allergy or significant renal failure)
• Any history or current evidence suggestive of venous or arterial thrombotic events within the previous
12 months, including clinical, ECG, laboratory, or imaging findings. Clinically silent chance findings of old
ischaemia are not considered exclusion criteria.
• Hereditary or acquired haemorrhagic diathesis or coagulation factor deficiency
• Use of heparin, low-molecular weight heparin, GPIIb/IIIa antagonist, or oral anticoagulation (e.g.
warfarin, factor Xa inhibitor, thrombin inhibitor) within the previous 14 days, irrespective of laboratory
values
• Pregnancy (women of childbearing potential must be tested)
• Planned surgery for ICH within 24 h
• Concurrent or planned treatment with haemostatic agents (e.g. PCC, vitamin K, fresh frozen plasma,
or platelet transfusion)
• Participation in any investigational study in the last 30 days
• Known terminal illness, or planned withdrawal of care or comfort care measures
• Any condition that in the judgment of the investigator could impose hazards to the patient if study
therapy is initiated, or affect the participation of the patient in the study
Interventions Intervention: intravenous tranexamic acid 1000 mg in 100 mL 0.9% normal saline over 10 minutes followed
by 1000 mg in 500 mL 0.9% normal saline infusion over 8 h
Comparator: intravenous placebo in 100 mL 0.9% normal saline over 10 minutes followed by 500 mL 0.9%
normal saline infusion over 8 h
Outcomes Primary outcome measures
• ICH growth by 24 ± 3 h as defined by either 33% or 6 mL increase from baseline, adjusted for baseline
ICH volume.
Secondary outcome measures
• Major thromboembolic events (MI, ischaemic stroke, PE), measured within 90 ± 7 days)
• Absolute ICH growth volume by 24 ± 3 h, adjusted for baseline ICH volume
• Absolute IVH growth volume by 24 ± 3 h, adjusted for baseline IVH volume
• mRS score of 0 to 4 at 3 months
• mRS score of 0 to 3 at 3 months
• Categorical shift in mRS at 3 months, subject to the validity of proportional odds assumption
• Death due to any cause by 3 months
Starting date December 2012
Contact information Atte Meretoja, The Florey Institute of Neuroscience and Mental Health
Notes NCT01702636
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NCT00699621
Trial name or title Platelet transfusion in acute intracerebral haemorrhage
Methods • To explore whether use of antiplatelet agents leads to a rapid enlargement of haematoma after onset of
acute ICH
• To explore the efficacy and safety of platelet transfusion for prevention of haematoma growth in people
who experienced acute ICH while on antiplatelet medication
Participants Inclusion criteria
• Taking either aspirin, clopidogrel, or a combination of aspirin and dipyridamole
• Acute primary ICH
• > 17 years
• Admitted within 6 h after onset of ICH
• ICH score < 4
Exclusion criteria
• Type of ICH other than acute primary ICH
• People who need neurosurgery
• Life expectancy < 3 months due to comorbid disorders
• Confirmed malignant disease (cancer)
• Confirmed acute MI
• Hepatitis, liver cirrhosis, or both
• Renal failure
• Infectious disease (HIV, endocarditis, etc)
• Current or previous haematologic disease
• Women of childbearing age, if pregnant
• Participation in another study within the preceding 30 days
Interventions Intervention: 4 units of fresh platelets will be infused immediately
Comparator: no platelet transfusion (open control)
Outcomes Primary outcome measures
• Haematoma growth within 24 h measured as increase in haematoma volume observed by head CT
(time frame: 24 h)
Secondary outcome measures
• GOS (time frame: 90 days)
• Cardiovascular death occurring within the treatment period (time frame: 90 days)
• Death due to any cause occurring within the treatment period (time frame: 90 days)
• Acute MI (time frame: 90 days)
• VTE (time frame: 90 days)
Starting date January 2009
Contact information Matti E Hillbom, Oulu University Central Hospital, Department of Neurology
Notes NCT00699621
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NCT00810888
Trial name or title The Spot Sign for Predicting and Treating ICH Growth study (STOP-IT)
Methods The purpose of this study is to determine if computed tomography angiography can predict which individuals
with ICH will experience significant growth in the size of the haemorrhage. For individuals who are at high
risk for haemorrhage growth, the study will compare the drug recombinant activated factor VII (rFVIIa) to
placebo to determine the effect of rFVIIa on ICH growth
Participants Inclusion criteria
• Acute, spontaneous ICH (including bleeding in cerebellum) diagnosed by non-enhanced CT scan
within 5 h of symptom onset. (Time of onset is defined as the last time the patient was witnessed to be at
baseline, i.e. people who have stroke symptoms upon awakening will be considered to have their onset at
beginning of sleep)
• Age ≥ 18 years through 80 years (candidates must have had their 18th birthday, but not had their 81st
birthday)
• For spot positive patients, dosing of study drug within 90 minutes of enrolling CT scan
Exclusion criteria
• Time of symptom onset of ICH is unknown or more than 5 h prior to baseline CT scan
• ICH secondary to known or suspected trauma, aneurysm, vascular malformation, haemorrhagic
conversion of ischaemic stroke, venous sinus thrombosis, thrombolytic treatment of any condition (e.g. MI,
cerebral infarction, etc), CNS tumour or CNS infection
• Brainstem location of haemorrhage (people with cerebellar haemorrhage may be enrolled)
• Serum creatinine > 1.4 mg/dL (123 µmol/L). Sites that currently perform CTA as standard of care for
ICH will follow their standard procedures regarding renal insufficiency
• Known allergy to iodinated contrast media
• Intravenous or intra-arterial administration of iodinated contrast media within the previous 24 h of
baseline CT scan
• Known hereditary (e.g. haemophilia) or acquired haemorrhagic diathesis, coagulation factor deficiency,
or anticoagulant therapy with INR > 1.2
• Known or suspected thrombocytopenia (unless current platelet count documented above 50,000/µL)
• Unfractionated heparin use with abnormal PTT
• Low-molecular weight heparin use within the previous 24 h
• GPIIb/IIIa antagonist use in the previous 2 weeks
• GCS score < 8 at time of proposed enrolment
• Pre-admission mRS score > 2
• Baseline ICH volume of < 0.5 cc (haematoma volume will be estimated by local investigators from the
baseline CT using the ABC/2 method)
• Baseline ICH volume > 90 cc
• Planned surgical evacuation of ICH within 24 h of symptom onset (placement of intraventricular
catheter is not a contraindication to study enrolment)
• Evidence of acute or subacute ischaemic stroke on baseline qualifying CT scan
• Clinical history of thromboembolism or ischaemic vascular disease, including MI, coronary artery
bypass surgery, cardiac angina, TIA, ischaemic stroke, peripheral artery disease (vascular claudication),
cerebral bypass surgery, carotid endarterectomy, deep venous thrombosis, pulmonary embolism, or coronary
or cerebrovascular angioplasty or stenting. (Clinically silent evidence of old ischaemia on EKG (Q waves) or
CT scan (silent old infarct) will not be considered reasons for exclusion)
• Baseline electrocardiogram shows evidence of acute cardiac ischaemia (ST elevation in 2 contiguous
leads, new LBBB, or ST depression)
• Clinical history suggestive of acute cardiac ischaemia (e.g. chest pain)
• Abnormal baseline troponin
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• Females of childbearing potential who are known to be pregnant, lactating, or who have positive
pregnancy tests on admission
• Advanced or terminal illness or any other condition the investigator feels would pose a significant
hazard to the patient if rFVIIa were administered
• Recent (within 30 days) participation in any investigational drug or device trial or earlier participation
in any investigational drug or device trial for which the duration of effect is expected to persist until the
time of STOP-IT enrolment
• Planned withdrawal of care or comfort care measures
• Person known or suspected of not being able to comply with trial protocol (e.g. due to alcoholism,
drug dependency or psychological disorder)
• Informed consent cannot be obtained from the patient or legally authorised representative
Interventions Intervention: recombinant activated factor VII. Participants will receive rFVIIa at 80 mcg/kg (maximum dose
volume 21.3 mL, equivalent to maximum weight of 160 kg)
Comparator: placebo. An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum
weight of 160 kg)
Outcomes Primary outcome measures: life-threatening thromboembolic complications defined as development of 1)
acute myocardial ischaemia, 2) acute cerebral ischaemia, and 3) acute pulmonary embolism (time frame:
through day 4 after completion of study drug). The rate of haematoma growth among spot sign positive
participants at 24 h, comparing participants treated with rFVIIa to those treated with placebo. Haematoma
growth will be defined as a > 33% or > 6 cc increase in volume (time frame: at 24 h).
The sensitivity and specificity of the spot sign for predicting haematoma growth (time frame: baseline head
CT scan within 5 h, followed by a CT angiogram. Haematoma growth determined by comparison with a
head CT scan performed at 24 h)
Secondary outcome measures: incidence of other potentially study drug-related thromboembolic complica-
tions, such as deep venous thrombosis and elevations in troponin not associated with ECG changes (time
frame: through day 4 after completion of study drug)
90-day outcomes among spot positive people, dichotomised as mRS score of 0 to 4 verses 5 to 6, comparing
participants treated with rFVIIa to those treated with placebo (time frame: 90 days (± 7 days) from time of
study enrolment). The positive and negative predictive values of the spot sign and the accuracy of the site
investigators for correct identification of the spot sign as compared to a blinded study neuroradiologist (time
frame: baseline head CT scan within 5 h, followed by a CT angiogram. Haematoma growth determined by
comparison with a head CT scan performed at 24 h. Rate of total haemorrhage volume growth (haematoma
+ IVH) among spot-positive participants (time frame: 24 h (± 3 h) from baseline CT scan)
Starting date November 2010
Contact information Matthew Flaherty, Associate Professor, University of Cincinnati
Notes NCT00810888
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NCT01359202
Trial name or title ’Spot Sign’ Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT)
Methods This clinical trial will enrol 110 participants from approximately 15 Canadian stroke centres. People coming
to the emergency department with bleeding in the brain not due to trauma or other known causes who can
be treated within 6 h of onset will undergo CT angiography using standard CT scanners (’CAT scan’). Those
with a ’spot sign’, a type of marker on the CT scan that shows the brain is still bleeding, will be randomly
assigned to a single injection of ’factor 7’ (a blood clotting drug used in haemophilia) or placebo (inactive
saline); people without a spot sign will not be treated. The researchers will look at howmuch bleeding happens
after the treatments are administered, as well as clinical outcomes such as death and disability. The researchers
think that factor 7 will cause the bleeding to stop faster and possibly decrease death and disability
Participants Inclusion criteria
• Acute spontaneous primary supratentorial ICH diagnosed by CT scan
• Presence of a spot sign within the haematoma on CTA source images
• Baseline ICH volume 3 mL to 90 mL
• Age 18 or older
• Investigator is able to randomise and administer study drug as soon as possible within a target of 60
minutes after CT angiogram and no later than 6 h after stroke symptom onset (using the ’last seen normal’
principle)
• Plan to provide full medical care for at least 24 h
• Assent-consent from participant or LAR prior to enrolment, or a waiver of consent (where REB
approved) if patient or LAR assent-consent is not possible prior to enrolment
Exclusion criteria
• Brainstem or cerebellar haemorrhage
• ICH secondary to known or suspected trauma, aneurysm, vascular malformation, hemorrhagic
conversion of ischaemic stroke, venous sinus thrombosis, thrombolytic treatment, tumour, or infection; or
an in-hospital ICH or ICH as a result of any in-hospital procedure or illness
• Baseline brain imaging shows evidence of acute or subacute ischaemic stroke (chronic infarcts are not
an exclusion)
• Contrast administration within the previous 24 h
• Evidence of thromboembolic risk factors, defined as any of the following: known history within the
past 6 months of any of the following: 1) MI, 2) coronary artery bypass surgery, 3) angina, 4) ischaemic
stroke, 5) TIA, 6) carotid endarterectomy, 7) cerebral bypass surgery, 8) deep venous thrombosis, 9)
pulmonary embolism, 10) any vascular angioplasty, stenting (coronary, peripheral vascular, or
cerebrovascular) or filter (e.g. vena cava filter); 11) prosthetic cardiac valve, and, or 12) known history of a
high-risk thrombophilia (e.g. antithrombin III deficiency, antiphospholipid antibody syndrome, protein C
deficiency, etc)
• Known hereditary (e.g. haemophilia) or acquired haemorrhagic diathesis or coagulation factor
deficiency
• Any known condition that the investigator feels would pose a significant hazard if rFVIIa were
administered
• Planned surgery for ICH within 24 h (placement of intraventricular catheter is not an exclusion)
• Planned withdrawal of care before 24 h post-ICH onset
• Known participation in another therapeutic trial
• Known allergy or other contraindication to iodinated contrast dye
• Known or suspected hypersensitivity to the trial product
• Known unfractionated heparin use - must check PTT and exclude if elevated above upper limit of
local lab’s reference range
• Known low-molecular weight heparin, heparinoid, factor X inhibitor, or direct thrombin inhibitor use
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within previous 7 days
• Known GPIIb/IIIa antagonist use in previous 2 weeks
• Known warfarin (or other anticoagulant) therapy with INR > 1.40. Note: if the patient is suspected to
have cirrhosis, study staff are to wait for the INR value prior to dosing, and ensure they do not enrol the
patient if the INR value is > 1.40. Otherwise, the physician should use their discretion if they believe the
patient is not at risk for elevated INR
• Concurrent or planned treatment with prothrombin complex concentrate, vitamin K, fresh frozen
plasma, or platelet transfusion
• Pregnancy or lactation. Women of childbearing potential must have a negative pregnancy test prior to
randomization.
• Current clinical symptoms suggestive of acute coronary ischaemia (e.g. chest pain).
• Baseline ECG evidence of acute coronary ischaemia (e.g. ST elevation in 2 contiguous leads, new
LBBB, ST depression)
• Baseline platelet count < 50,000, INR > 1.40, or elevated PTT
Interventions Intrevention: rfVIIa 80 ug/kg IV bolus
Comparator: placebo standard saline solution
Outcomes Primary outcome measures
• ICH size: difference between groups in ICH size on CT scan at 24 h post-dose, adjusted for baseline
ICH size
Secondary outcome measures:
• Feasibility (time frame: 0): percentage of sites that can meet recruitment targets of 2 patients per site
per year; % of patients who meet the target time of < 45 minutes from emergency department arrival to the
start of the scan; % of patients who meet the target time of < 60 minutes from the end of the CT angiogram
to administration of study drug; local site spot sign interpretation accuracy as judged by central adjudicator;
protocol violations; waiver of consent process, evaluation, and effectiveness (time frame: 4.90 days); waiver
of consent use, acceptability, and effect on treatment times. Questionnaire will be administered to subject or
LAR at 4 days and 90 days
• Acute blood pressure control (time frame: 1 h): % of participants in whom blood pressure control was
achieved, defined as achieving systolic BP < 180 mmHg within 1 h post-randomisation
• Thromboembolic events : incidence of MI and ischaemic stroke within 4 days; any other arterial or
venous thromboembolic SAEs within 4 days
• Mortality : 90-day mortality rate
• Unstable angina: unstable angina within 4 days of treatment
• Troponin increase : troponin rise above upper limit of normal within 4 days (without clinical
symptoms or ECG evidence of acute coronary syndrome)
• DVT : deep venous thrombosis (DVT) within 4 days
• Pulmonary embolism : PE within 30 days
• Cognition : Montreal Cognitive Assessment (MoCA) and Stroke Impact Scale at 90 days and 1 year
• Disability : proportion of participants with mRS score 5 to 6 (death or severe disability) at 90 days and
1 year
Starting date May 2011
Contact information Dr David Gladstone, Sunnybrook Health Sciences Centre
Notes NCT01359202
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NCT02777424
Trial name or title Prothrombin complex concentrate versus fresh frozen plasma to correct coagulation disorders in adult neu-
rosurgical patients (CLOT-CRANE)
Methods This prospective, randomized, multicentre study is performed to determine whether prothrombin complex
concentrates confers any benefits over fresh frozen plasma in adult neurological patients with coagulation
disorders (PT value less than 60%)
Participants Inclusion criteria
• People with spontaneous ICH, traumatic ICH, or people requiring neurological surgery
• Coagulation disorder defined by PT < 60%
Exclusion criteria
• Concomitant use of oral anticoagulant drugs
• Acquired deficiency of coagulation factors whose treatment is established
• Hypersensitivity to a PCC
• History of thrombocytopenia induced by heparin
• Disseminated intravascular coagulation
• Extracranial active bleeding
• Hypersensitivity to vitamin K
Interventions Intervention: PCC. Administration of a single dose of PCC (25 U/kg equivalent factor IX)
Comparator: fresh frozen plasma. Administration of a single dose of fresh frozen plasma of 15 mL/kg
Outcomes Primary outcome measures
• Proportion of participants with correction of prothrombin time (PT < 60% at end of treatment
administration - an average of 1 h)
Starting date January 2016
Contact information Laurence Salomon, Fondation Ophtalmologique Adolphe de Rothschild
Notes NCT02777424
NCT02866838
Trial name or title Treatment of intracerebral hemorrhage in patients on non-vitamin K antagonist (TICH-NOAC)
Methods NOACs target selected players in the coagulation cascade as the direct thrombin inhibitor dabigatran and
the factor Xa-inhibitors apixaban and rivaroxaban. ICH is the most feared complication of NOAC treatment
(NOAC-ICH)
Outcome of NOAC-ICH can be devastating and is a major cause of death and disability. There is no
proven treatment for NOAC-ICH. Haematoma expansion (HE) is associated with unfavourable outcome.
Tranexamic acid (TA) is an anti-fibrinolytic drug that is used in a number of bleeding conditions other than
ICH
Participants Inclusion criteria
• Acute ICH (symptom onset < 12 h)
• Prior treatment with a novel direct oral anticoagulant (apixaban, dabigatran, edoxaban, or rivaroxaban;
last intake < 48 h or proven NOAC activity by relevant coagulation assays)
• Age > 18 years, no upper age limit
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• Informed consent has been received in accordance to local ethics committee requirements
Exclusion criteria
• Severe pre-morbid disability (mRS > 4)
• Anticoagulation with vitamin K antagonists (VKA; recent intake)
• Secondary ICH (e.g. AVM, tumour, trauma). Note: it is not necessary for investigators to exclude
underlying structural abnormality prior to enrolment, but where an underlying structural abnormality is
already known, these people should not be recruited.
• GCS < 5
• Pregnancy
• Planned neurosurgical haematoma evacuation within 24 h (before follow-up imaging)
• PE or DVT within the last 2 weeks
Interventions Intervention: intravenous tranexamic acid: 1 g loading dose given as 100 mL infusion over 10 minutes,
followed by another 1 g in 250 mL infused over 8 h
Comparator: placebo: saline 0.9% given in identical dosage as experimental drug
Outcomes Primary outcome measures
• Haematoma expansion (time frame: up to 27 h ): change in ICH-volume between baseline CT and
follow-up CT at 24 ± 3 h of 33% relative or 6 mL absolute increase
Secondary outcome measures:
• mRS 0 to 4 at month 3
• mRS 0 to 3 at month 3
• Categorical shift in mRS at month 3
• Mortality due to any cause at month 3
• In-hospital mortality (time frame: baseline until discharge from hospital - hospital stays last, on
average, 10 days)
• Absolute ICH growth volume by 24 ± 3 h, adjusted for baseline ICH volume
• Symptomatic HE defined as HE plus a neurological deterioration of NIHSS > 4 points or GCS > 2
points
• Number of major thromboembolic events (MI, ischaemic stroke, PE - safety endpoints; 3 months)
• Number of neurosurgical interventions (including craniectomy, external ventricular drain, haematoma
evacuation; 3 months)
Starting date December 2016
Contact information Philippe Lyrer, Stroke Center and Neurology, University Hospital Basel
Notes NCT02866838
NCT03044184
Trial name or title Tranexamic acid for spontaneous acute cerebral hemorrhage trial (TRANSACT)
Methods This study aims to explore the effectiveness of tranexamic acid (also known as transamine or TXA) in reducing
haematoma expansion in people with haemorrhagic stroke when given in the acute phase
Participants Inclusion criteria
• People with CT evidence of supratentorial ICH
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• Initiation of trial medication within 3 h from the time of symptoms onset
• Ethnic Chinese
• Reasonable expectation of completion of outcome measures at follow-up
• Written informed consent from either the patient, next-of-kin, or legal guardian
Exclusion criteria
• Patients not expected to survive 24 h after admission
• Patients with brainstem herniation syndrome on admission
• Patients who need immediate neurosurgical intervention
• GCS of 5 or less on admission i.e. a GCS score of 2 according to the Hemphil ICH score
• Previous antiplatelet and anticoagulant medication use
• Known thrombocytopenia or coagulopathy
• Disseminated intravascular coagulation on admission
• Acute sepsis on admission
• ICH secondary to intracranial vascular lesion: aneurysm, AVM, neoplasm, or dural venous sinus
thrombosis
• Previous venous thromboembolic disease: DVT
• History of ischaemic stroke or TIA within 12 months
• History of ischaemic heart disease or MI
• History of peripheral vascular disease
• Patients with previous disability (prestroke mRS score > 2)
• Pregnancy or breast feeding
• History of allergy to tranexamic acid
Interventions Intervention: standard management for people with spontaneous ICH according to 2015 AHA/ASA Guide-
lines for the Management of Intracerebral Hemorrhage. Participants will have 1 g of tranexamic acid (diluted
in 100 mL of normal saline 0.9%) intravenously infused over 10 minutes, within 3 h of symptom presenta-
tion, and another 1 g of tranexamic acid (diluted in 100 mL of normal saline 0.9%) infused over 8 h
Comparator: standard management for participants with spontaneous ICH according to 2015 AHA/ASA
Guidelines for the Management of Intracerebral Hemorrhage. Participants will have 100 mL of normal saline
0.9% intravenously infused over 10 minutes within 3 h of symptom presentation, and another 100 mL of
normal saline 0.9% infused over 8 h
Outcomes Primary outcome measures
• ICH volume (by CT brain scan) at 6 h: intracerebral haematoma volume (mL) as assessed by CT brain
scan
• ICH volume (by CT brain scan) at 24 h: intracerebral haematoma volume (mL) as assessed by CT
brain scan
• ICH volume (by CT brain scan) at 1 week: intracerebral haematoma volume (mL) as assessed by CT
brain scan
Secondary outcome measures
• GOS ( at 3 months and 6 months after stroke)
• mRS (at 3 months and 6 months after stroke)
• Stroke-specific quality of life scale ( at 3 months and 6 months after stroke)
• 30-day mortality : all-cause mortality within 30 days of admission
• Vascular occlusive events (at 30 days after admission): ischaemic stroke, MI, PE, DVT
• Rate of seizures: rate of seizures within 30 days of stroke
• Tranexamic acid-associated adverse effects (at 30 days after admission): intolerable gastrointestinal
symptoms, such as dyspepsia, diarrhoea, vomiting. Allergic reaction to tranexamic acid
• Need for neurosurgical intervention (at 30 days after admission): need for operative management of
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the haemorrhagic stroke
Starting date 1 April 2017
Contact information Peter YM Woo, Neurosurgery, Kwong Wah Hospital
Notes NCT03044184
NOR-ICH
Trial name or title The Norwegian Intracerebral Haemorrhage trial (NOR-ICH)
Methods Multicentre prospective randomized, open-label, blinded endpoint (PROBE) trial. There are 2 arms in the
study: arm A treats participants presenting within 2.5 h from onset, and arm B treats participants presenting
between 2.5 and 4.5 h
Participants The trial aims to recruit 500 participants, aged 18 years to 80 years, over 4 years
Interventions Intervention: intravenous tranexamic acid 1 g bolus followed by 1 g at 2 h, 4 h, and 8 h from the first dose,
lasting for 28 h in total
Comparator: open control
Outcomes Primary outcome: haematoma expansion at 24 h
Secondary outcomes: increase in NIHSS score within 36 h, NIHSS at day 7, mRS at day 90, and symptomatic
thromboembolic events within 7 days
Starting date 2012
Contact information
Notes This information is based on a record we found at helseforskning.etikkom.no/prosjekterirek/prosjektregister/
prosjekt?p document id=324797
Sprigg 2016 (TICH-2)
Trial name or title Tranexamic acid for IntraCerebral Haemorrhage (TICH-2)
Methods A pragmatic phase III prospective double-blind randomised placebo-controlled trial
Participants Inclusion criteria
• Adults with acute spontaneous ICH
• Within 8 h of stroke symptom onset or time last seen well
Exclusion criteria
• People with ICH secondary to anticoagulation, thrombolysis or known underlying structural
abnormality such as AVM, aneurysm, tumour, or venous thrombosis. An underlying structural abnormality
does not need to be excluded before enrolment, but where known, patients should not be recruited
• Contraindication to tranexamic acid
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• Premorbid dependency (mRS > 4)
• Concurrent participation in another drug or device trial. Participants enrolled in TICH-2 may be
enrolled into the RESTART trial after 21 days
• Prestroke life expectancy
Target sample size 2000
Interventions Intervention: intravenous tranexamic acid: 1 g loading dose given as 100 mL infusion over 10 minutes,
followed by another 1 g in 250 mL infused over 8 h
Comparator: matching placebo (normal saline 0.9%) administered by identical regimen
Outcomes Primary outcome measure: to assess whether tranexamic acid is safe and reduces death or dependency after
primary ICH. Death or dependency (ordinal shift on mRS) at day 90 will be analysed by intention-to-
treat using ordinal logistic regression (OLR), with adjustment for minimisation factors. The assumption of
proportional odds will be tested using the likelihood ratio test. Comparison of tranexamic acid versus control
Secondary outcome measures
• At day 7 (or discharge if sooner), neurological impairment (NIHSS)
• At day 90, disability (BI), Quality of Life (EuroQoL), cognition, cognition and mood (TICS and ZDS)
• Safety: death, serious adverse events, thromboembolic events, seizures
• Costs: length of hospital stay, re-admission, institutionalisation
• Radiological efficacy and safety (CT scan): change in haematoma volume from baseline to 24 h,
haematoma location, and new infarction
Starting date 1 March 2013
Contact information Prof Nikola Sprigg, University of Nottingham
Notes ISRCTN93732214
AVM: arteriovenous malformation
BI: Barthel Index
CT: computed tomography
CTA: computed tomography angiography
DVT: deep vein thrombosis
ECG: electrocardiogram
GCS: Glasgow Coma Score
GOS: Glasgow Outcome Scale
h: hour(s)
ICH: intracerebral haemorrhage
INR: international normalised ratio
IVH: intraventricular haemorrhage
MI: myocardial infarction
mRS: modified Rankin Scale
NIHSS: National Institutes of Health Stroke Scale
NOAC: non-vitamin K antagonist oral anticoagulants
PCC: prothrombin complex concentrate
PE: pulmonary embolism
RCT: randomised controlled trial
SAE: serious adverse event
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SAH: subarachnoid haemorrhage
SBP: systolic blood pressure
TIA: transient ischaemic attack
VTE: venous thromboembolism
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D A T A A N D A N A L Y S E S
Comparison 1. Blood clotting factors vs placebo or open control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or dependence (mRS 4 to
6) at day 90
6 1390 Risk Ratio (IV, Random, 95% CI) 0.87 [0.70, 1.07]
1.1 Acute spontaneous ICH 5 1369 Risk Ratio (IV, Random, 95% CI) 0.86 [0.66, 1.11]
1.2 Acute spontaneous ICH
undergoing craniotomy
1 21 Risk Ratio (IV, Random, 95% CI) 0.88 [0.59, 1.31]
2 Death or dependence (GOS-E 1
to 4) at day 90
3 486 Risk Ratio (IV, Random, 95% CI) 0.90 [0.81, 1.01]
2.1 Acute spontaneous ICH 3 486 Risk Ratio (IV, Random, 95% CI) 0.90 [0.81, 1.01]
3 Death by day 90 7 1480 Risk Ratio (IV, Random, 95% CI) 0.75 [0.51, 1.09]
3.1 Acute spontaneous ICH 6 1459 Risk Ratio (IV, Random, 95% CI) 0.71 [0.44, 1.14]
3.2 Acute spontaneous ICH
undergoing craniotomy
1 21 Risk Ratio (IV, Random, 95% CI) 0.86 [0.41, 1.80]
4 All serious adverse events 2 87 Risk Ratio (IV, Random, 95% CI) 0.81 [0.30, 2.22]
4.1 Acute spontaneous ICH 2 87 Risk Ratio (IV, Random, 95% CI) 0.81 [0.30, 2.22]
5 Thromboembolic serious adverse
events
5 1398 Risk Ratio (IV, Random, 95% CI) 1.24 [0.80, 1.91]
5.1 Acute spontaneous ICH 5 1398 Risk Ratio (IV, Random, 95% CI) 1.24 [0.80, 1.91]
6 Intracerebral haemorrhage
growth by 24 hours
3 151 Risk Ratio (IV, Random, 95% CI) 0.74 [0.36, 1.48]
6.1 Acute spontaneous ICH 3 151 Risk Ratio (IV, Random, 95% CI) 0.74 [0.36, 1.48]
Comparison 2. Antifibrinolytic drugs vs placebo or open control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or dependence (mRS 4 to
6) at day 90
1 24 Risk Ratio (IV, Random, 95% CI) 1.25 [0.57, 2.75]
1.1 Acute spontaneous ICH 1 24 Risk Ratio (IV, Random, 95% CI) 1.25 [0.57, 2.75]
2 Death by day 90 3 57 Risk Ratio (IV, Random, 95% CI) 1.16 [0.31, 4.39]
2.1 Acute spontaneous ICH 3 57 Risk Ratio (IV, Random, 95% CI) 1.16 [0.31, 4.39]
3 All serious adverse events 1 24 Risk Ratio (IV, Random, 95% CI) 1.5 [0.39, 5.83]
3.1 Acute spontaneous ICH 1 24 Risk Ratio (IV, Random, 95% CI) 1.5 [0.39, 5.83]
4 Thromboembolic serious adverse
events
1 24 Risk Ratio (IV, Random, 95% CI) 1.59 [0.07, 35.15]
4.1 Acute spontaneous ICH 1 24 Risk Ratio (IV, Random, 95% CI) 1.59 [0.07, 35.15]
5 Barthel Index 1 24 Mean Difference (IV, Random, 95% CI) -22.50 [-45.65, 0.
65]
5.1 Acute spontaneous ICH 1 24 Mean Difference (IV, Random, 95% CI) -22.50 [-45.65, 0.
65]
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6 EuroQoL health utility score 1 24 Mean Difference (IV, Random, 95% CI) -0.04 [-0.35, 0.27]
6.1 Acute spontaneous ICH 1 24 Mean Difference (IV, Random, 95% CI) -0.04 [-0.35, 0.27]
7 Intracerebral haemorrhage
growth by 24 hours
3 57 Risk Ratio (IV, Random, 95% CI) 0.76 [0.56, 1.05]
7.1 Acute spontaneous ICH 3 57 Risk Ratio (IV, Random, 95% CI) 0.76 [0.56, 1.05]
Comparison 3. Platelet transfusion vs open control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or dependence (mRS 4 to
6) at day 90
1 190 Risk Ratio (IV, Random, 95% CI) 1.29 [1.04, 1.61]
1.1 Acute antiplatelet-
associated ICH
1 190 Risk Ratio (IV, Random, 95% CI) 1.29 [1.04, 1.61]
2 Death by day 90 1 190 Risk Ratio (IV, Random, 95% CI) 1.42 [0.88, 2.28]
2.1 Acute antiplatelet-
associated ICH
1 190 Risk Ratio (IV, Random, 95% CI) 1.42 [0.88, 2.28]
3 All serious adverse events 1 190 Risk Ratio (IV, Random, 95% CI) 1.46 [0.98, 2.16]
3.1 Acute antiplatelet-
associated ICH
1 190 Risk Ratio (IV, Random, 95% CI) 1.46 [0.98, 2.16]
4 Thromboembolic serious adverse
events
1 190 Risk Ratio (IV, Random, 95% CI) 3.84 [0.44, 33.68]
4.1 Acute antiplatelet-
associated ICH
1 190 Risk Ratio (IV, Random, 95% CI) 3.84 [0.44, 33.68]
5 Intracerebral haemorrhage
growth by 24 hours
1 190 Risk Ratio (IV, Random, 95% CI) 1.11 [0.56, 2.20]
5.1 Acute antiplatelet-
associated ICH
1 190 Risk Ratio (IV, Random, 95% CI) 1.11 [0.56, 2.20]
Comparison 4. Blood clotting factors vs fresh frozen plasma
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death by day 90 1 5 Risk Ratio (IV, Random, 95% CI) 0.27 [0.02, 3.74]
1.1 Acute anticoagulant-
associated ICH
1 5 Risk Ratio (IV, Random, 95% CI) 0.27 [0.02, 3.74]
2 All serious adverse events 1 5 Risk Ratio (IV, Random, 95% CI) 0.27 [0.02, 3.74]
2.1 Acute anticoagulant-
associated ICH
1 5 Risk Ratio (IV, Random, 95% CI) 0.27 [0.02, 3.74]
54Haemostatic therapies for acute spontaneous intracerebral haemorrhage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Blood clotting factors vs placebo or open control, Outcome 1 Death or
dependence (mRS 4 to 6) at day 90.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 1 Blood clotting factors vs placebo or open control
Outcome: 1 Death or dependence (mRS 4 to 6) at day 90
Study or subgroup
Blood
clotting
factor(s)
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Mayer 2005b 160/303 66/96 32.3 % 0.77 [ 0.65, 0.91 ]
Mayer 2005a 16/36 5/11 6.7 % 0.98 [ 0.46, 2.06 ]
Mayer 2006 15/32 4/8 6.1 % 0.94 [ 0.43, 2.06 ]
Mayer 2008 (FAST) 269/557 120/262 33.4 % 1.05 [ 0.90, 1.23 ]
Li 2012 5/32 13/32 4.8 % 0.38 [ 0.16, 0.95 ]
Subtotal (95% CI) 960 409 83.3 % 0.86 [ 0.66, 1.11 ]
Total events: 465 (Blood clotting factor(s)), 208 (Placebo/open control)
Heterogeneity: Tau2 = 0.04; Chi2 = 10.59, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Acute spontaneous ICH undergoing craniotomy
Imbert 2012 (PRE-SICH) 10/13 7/8 16.7 % 0.88 [ 0.59, 1.31 ]
Subtotal (95% CI) 13 8 16.7 % 0.88 [ 0.59, 1.31 ]
Total events: 10 (Blood clotting factor(s)), 7 (Placebo/open control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 973 417 100.0 % 0.87 [ 0.70, 1.07 ]
Total events: 475 (Blood clotting factor(s)), 215 (Placebo/open control)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.61, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.2 0.5 1 2 5
Favours clotting factors Favours placebo/control
55Haemostatic therapies for acute spontaneous intracerebral haemorrhage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Blood clotting factors vs placebo or open control, Outcome 2 Death or
dependence (GOS-E 1 to 4) at day 90.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 1 Blood clotting factors vs placebo or open control
Outcome: 2 Death or dependence (GOS-E 1 to 4) at day 90
Study or subgroup
Blood
clotting
factor(s)
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Mayer 2005a 24/36 7/11 4.9 % 1.05 [ 0.63, 1.73 ]
Mayer 2005b 221/303 78/96 89.7 % 0.90 [ 0.80, 1.01 ]
Mayer 2006 20/32 6/8 5.4 % 0.83 [ 0.51, 1.35 ]
Total (95% CI) 371 115 100.0 % 0.90 [ 0.81, 1.01 ]
Total events: 265 (Blood clotting factor(s)), 91 (Placebo/open control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours clotting factors Favours placebo/control
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Analysis 1.3. Comparison 1 Blood clotting factors vs placebo or open control, Outcome 3 Death by day 90.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 1 Blood clotting factors vs placebo or open control
Outcome: 3 Death by day 90
Study or subgroup
Blood
clotting
factor(s)
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Mayer 2005a 3/36 2/11 4.7 % 0.46 [ 0.09, 2.40 ]
Mayer 2005b 56/303 28/96 30.7 % 0.63 [ 0.43, 0.94 ]
Mayer 2006 7/32 1/8 3.5 % 1.75 [ 0.25, 12.26 ]
F7ICH-1602 2007 0/45 0/45 Not estimable
Mayer 2008 (FAST) 112/557 51/262 35.6 % 1.03 [ 0.77, 1.39 ]
Li 2012 3/32 12/32 8.6 % 0.25 [ 0.08, 0.80 ]
Subtotal (95% CI) 1005 454 83.2 % 0.71 [ 0.44, 1.14 ]
Total events: 181 (Blood clotting factor(s)), 94 (Placebo/open control)
Heterogeneity: Tau2 = 0.13; Chi2 = 9.03, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 1.42 (P = 0.16)
2 Acute spontaneous ICH undergoing craniotomy
Imbert 2012 (PRE-SICH) 7/13 5/8 16.8 % 0.86 [ 0.41, 1.80 ]
Subtotal (95% CI) 13 8 16.8 % 0.86 [ 0.41, 1.80 ]
Total events: 7 (Blood clotting factor(s)), 5 (Placebo/open control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 1018 462 100.0 % 0.75 [ 0.51, 1.09 ]
Total events: 188 (Blood clotting factor(s)), 99 (Placebo/open control)
Heterogeneity: Tau2 = 0.08; Chi2 = 9.05, df = 5 (P = 0.11); I2 =45%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
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Analysis 1.4. Comparison 1 Blood clotting factors vs placebo or open control, Outcome 4 All serious
adverse events.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 1 Blood clotting factors vs placebo or open control
Outcome: 4 All serious adverse events
Study or subgroup
Blood
clotting
factor(s)
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Mayer 2005a 9/36 3/11 80.5 % 0.92 [ 0.30, 2.81 ]
Mayer 2006 2/32 1/8 19.5 % 0.50 [ 0.05, 4.85 ]
Total (95% CI) 68 19 100.0 % 0.81 [ 0.30, 2.22 ]
Total events: 11 (Blood clotting factor(s)), 4 (Placebo/open control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Blood clotting factors vs placebo or open control, Outcome 5 Thromboembolic
serious adverse events.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 1 Blood clotting factors vs placebo or open control
Outcome: 5 Thromboembolic serious adverse events
Study or subgroup
Blood
clotting
factor(s)
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Mayer 2005b 21/303 2/96 9.1 % 3.33 [ 0.79, 13.93 ]
Mayer 2005a 1/37 1/11 2.6 % 0.30 [ 0.02, 4.37 ]
Mayer 2006 3/32 1/8 4.1 % 0.75 [ 0.09, 6.29 ]
F7ICH-1602 2007 1/45 2/45 3.3 % 0.50 [ 0.05, 5.32 ]
Mayer 2008 (FAST) 55/558 21/263 80.8 % 1.23 [ 0.76, 2.00 ]
Total (95% CI) 975 423 100.0 % 1.24 [ 0.80, 1.91 ]
Total events: 81 (Blood clotting factor(s)), 27 (Placebo/open control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.69, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Blood clotting factors vs placebo or open control, Outcome 6 Intracerebral
haemorrhage growth by 24 hours.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 1 Blood clotting factors vs placebo or open control
Outcome: 6 Intracerebral haemorrhage growth by 24 hours
Study or subgroup
Blood
clotting
factor(s)
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Mayer 2005a 8/36 1/11 10.8 % 2.44 [ 0.34, 17.46 ]
Mayer 2006 23/32 7/8 61.2 % 0.82 [ 0.58, 1.15 ]
Li 2012 4/32 11/32 28.0 % 0.36 [ 0.13, 1.02 ]
Total (95% CI) 100 51 100.0 % 0.74 [ 0.36, 1.48 ]
Total events: 35 (Blood clotting factor(s)), 19 (Placebo/open control)
Heterogeneity: Tau2 = 0.18; Chi2 = 3.48, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Antifibrinolytic drugs vs placebo or open control, Outcome 1 Death or
dependence (mRS 4 to 6) at day 90.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 2 Antifibrinolytic drugs vs placebo or open control
Outcome: 1 Death or dependence (mRS 4 to 6) at day 90
Study or subgroup Antifibrinolytic
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Sprigg 2014 (TICH-1) 10/16 4/8 100.0 % 1.25 [ 0.57, 2.75 ]
Total (95% CI) 16 8 100.0 % 1.25 [ 0.57, 2.75 ]
Total events: 10 (Antifibrinolytic), 4 (Placebo/open control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours antifibrinolytic Favours placebo/control
61Haemostatic therapies for acute spontaneous intracerebral haemorrhage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Antifibrinolytic drugs vs placebo or open control, Outcome 2 Death by day 90.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 2 Antifibrinolytic drugs vs placebo or open control
Outcome: 2 Death by day 90
Study or subgroup Antifibrinolytic
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Zazulia 2001 (ATICH) 2/2 0/1 29.3 % 3.33 [ 0.29, 38.75 ]
Sprigg 2014 (TICH-1) 3/16 2/8 70.7 % 0.75 [ 0.16, 3.62 ]
Arumugam 2015 0/15 0/15 Not estimable
Total (95% CI) 33 24 100.0 % 1.16 [ 0.31, 4.39 ]
Total events: 5 (Antifibrinolytic), 2 (Placebo/open control)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Antifibrinolytic drugs vs placebo or open control, Outcome 3 All serious
adverse events.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 2 Antifibrinolytic drugs vs placebo or open control
Outcome: 3 All serious adverse events
Study or subgroup Antifibrinolytic
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Sprigg 2014 (TICH-1) 6/16 2/8 100.0 % 1.50 [ 0.39, 5.83 ]
Total (95% CI) 16 8 100.0 % 1.50 [ 0.39, 5.83 ]
Total events: 6 (Antifibrinolytic), 2 (Placebo/open control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Antifibrinolytic drugs vs placebo or open control, Outcome 4 Thromboembolic
serious adverse events.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 2 Antifibrinolytic drugs vs placebo or open control
Outcome: 4 Thromboembolic serious adverse events
Study or subgroup Antifibrinolytic
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Sprigg 2014 (TICH-1) 1/16 0/8 100.0 % 1.59 [ 0.07, 35.15 ]
Total (95% CI) 16 8 100.0 % 1.59 [ 0.07, 35.15 ]
Total events: 1 (Antifibrinolytic), 0 (Placebo/open control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Antifibrinolytic drugs vs placebo or open control, Outcome 5 Barthel Index.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 2 Antifibrinolytic drugs vs placebo or open control
Outcome: 5 Barthel Index
Study or subgroup Antifibrinolytic
Placebo/open
control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Sprigg 2014 (TICH-1) 16 59.2 (39.7) 8 81.7 (18.1) 100.0 % -22.50 [ -45.65, 0.65 ]
Total (95% CI) 16 8 100.0 % -22.50 [ -45.65, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.057)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Antifibrinolytic drugs vs placebo or open control, Outcome 6 EuroQoL health
utility score.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 2 Antifibrinolytic drugs vs placebo or open control
Outcome: 6 EuroQoL health utility score
Study or subgroup Antifibrinolytic
Placebo/open
control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Sprigg 2014 (TICH-1) 16 0.5 (0.5) 8 0.54 (0.27) 100.0 % -0.04 [ -0.35, 0.27 ]
Total (95% CI) 16 8 100.0 % -0.04 [ -0.35, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Antifibrinolytic drugs vs placebo or open control, Outcome 7 Intracerebral
haemorrhage growth by 24 hours.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 2 Antifibrinolytic drugs vs placebo or open control
Outcome: 7 Intracerebral haemorrhage growth by 24 hours
Study or subgroup Antifibrinolytic
Placebo/open
control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute spontaneous ICH
Arumugam 2015 11/15 15/15 96.4 % 0.74 [ 0.54, 1.02 ]
Sprigg 2014 (TICH-1) 3/16 1/8 2.2 % 1.50 [ 0.18, 12.22 ]
Zazulia 2001 (ATICH) 1/2 0/1 1.4 % 2.00 [ 0.14, 28.42 ]
Total (95% CI) 33 24 100.0 % 0.76 [ 0.56, 1.05 ]
Total events: 15 (Antifibrinolytic), 16 (Placebo/open control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.092)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Platelet transfusion vs open control, Outcome 1 Death or dependence (mRS 4
to 6) at day 90.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 3 Platelet transfusion vs open control
Outcome: 1 Death or dependence (mRS 4 to 6) at day 90
Study or subgroup Platelet transfusion Open control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute antiplatelet-associated ICH
Baharoglu 2016 (PATCH) 70/97 52/93 100.0 % 1.29 [ 1.04, 1.61 ]
Total (95% CI) 97 93 100.0 % 1.29 [ 1.04, 1.61 ]
Total events: 70 (Platelet transfusion), 52 (Open control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Platelet transfusion vs open control, Outcome 2 Death by day 90.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 3 Platelet transfusion vs open control
Outcome: 2 Death by day 90
Study or subgroup Platelet transfusion Open control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute antiplatelet-associated ICH
Baharoglu 2016 (PATCH) 31/97 21/93 100.0 % 1.42 [ 0.88, 2.28 ]
Total (95% CI) 97 93 100.0 % 1.42 [ 0.88, 2.28 ]
Total events: 31 (Platelet transfusion), 21 (Open control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Platelet transfusion vs open control, Outcome 3 All serious adverse events.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 3 Platelet transfusion vs open control
Outcome: 3 All serious adverse events
Study or subgroup Platelet transfusion Open control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute antiplatelet-associated ICH
Baharoglu 2016 (PATCH) 41/97 27/93 100.0 % 1.46 [ 0.98, 2.16 ]
Total (95% CI) 97 93 100.0 % 1.46 [ 0.98, 2.16 ]
Total events: 41 (Platelet transfusion), 27 (Open control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Platelet transfusion vs open control, Outcome 4 Thromboembolic serious
adverse events.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 3 Platelet transfusion vs open control
Outcome: 4 Thromboembolic serious adverse events
Study or subgroup Platelet transfusion Open control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute antiplatelet-associated ICH
Baharoglu 2016 (PATCH) 4/97 1/93 100.0 % 3.84 [ 0.44, 33.68 ]
Total (95% CI) 97 93 100.0 % 3.84 [ 0.44, 33.68 ]
Total events: 4 (Platelet transfusion), 1 (Open control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Platelet transfusion vs open control, Outcome 5 Intracerebral haemorrhage
growth by 24 hours.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 3 Platelet transfusion vs open control
Outcome: 5 Intracerebral haemorrhage growth by 24 hours
Study or subgroup Platelet transfusion Open control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute antiplatelet-associated ICH
Baharoglu 2016 (PATCH) 15/97 13/93 100.0 % 1.11 [ 0.56, 2.20 ]
Total (95% CI) 97 93 100.0 % 1.11 [ 0.56, 2.20 ]
Total events: 15 (Platelet transfusion), 13 (Open control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Blood clotting factors vs fresh frozen plasma, Outcome 1 Death by day 90.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 4 Blood clotting factors vs fresh frozen plasma
Outcome: 1 Death by day 90
Study or subgroup
Blood
clotting
factor(s) Fresh frozen plasma Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute anticoagulant-associated ICH
Boulis 1999 0/2 2/3 100.0 % 0.27 [ 0.02, 3.74 ]
Total (95% CI) 2 3 100.0 % 0.27 [ 0.02, 3.74 ]
Total events: 0 (Blood clotting factor(s)), 2 (Fresh frozen plasma)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Blood clotting factors vs fresh frozen plasma, Outcome 2 All serious adverse
events.
Review: Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Comparison: 4 Blood clotting factors vs fresh frozen plasma
Outcome: 2 All serious adverse events
Study or subgroup
Blood
clotting
factor(s) Fresh frozen plasma Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Acute anticoagulant-associated ICH
Boulis 1999 0/2 2/3 100.0 % 0.27 [ 0.02, 3.74 ]
Total (95% CI) 2 3 100.0 % 0.27 [ 0.02, 3.74 ]
Total events: 0 (Blood clotting factor(s)), 2 (Fresh frozen plasma)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 11) in the
Cochrane Library (searched 27 November 2017)
#1 [mh hemostatics]
#2 [mh “Blood Coagulation Factors”]
#3 [mh ˆhemostasis/DE] or [mh ˆ“blood coagulation”/DE] or [mh ˆfibrinolysis/DE] or [mh “platelet activation”/DE] or [mh an-
tithrombins] or [mh ˆthrombin/AI]
#4 ((haemosta* or hemosta* or antihaemorrhag* or antihemorrhag*) near/5 (drug* or agent* or treat* or therap*)):ti,ab
#5 (antifibrinolytic* or coagulat* next factor* or clotting next factor* or aminocaproic next acid or 6-aminocaproic next acid or
“tranexamic acid” or aprotinin or factor next VII* or “factor 7” or “factor 7a” or NovoSeven or thrombin next inhib* or argatroban):
ti,ab
#6 [mh ˆ“platelet transfusion”] or [mh ˆ“blood component transfusion”]
#7 [mh ˆ“blood platelets”]
#8 (infus* or transfus*):ti,ab
#9 #7 and #8
#10 ((platelet* or thrombocyte* or blood component*) near/5 (transfus* or infus*)):ti,ab
#11 #1 or #2 or #3 or #4 or #5 or #6 or #9 or #10
#12 [mh “basal ganglia haemorrhage”] or [mh ˆ“intracranial hemorrhages”] or [mh ˆ“cerebral haemorrhage”] or [mh ˆ“intracranial
hemorrhage, hypertensive”]
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#13 ((brain* or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal next gangli* or putaminal or putamen or posterior next fossa or hemispher* or stroke or apoplex*) near/5
(haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed*)):ti,ab
#14 (ICH or ICHs):ti,ab
#15 #12 or #13 or #14
#16 #11 and #15
Appendix 2. MEDLINE Ovid (1946 to 27 November 2017)
1. exp hemostatics/
2. exp Blood Coagulation Factors/
3. hemostasis/de or blood coagulation/de or fibrinolysis/de or exp platelet activation/de or exp antithrombins/ or thrombin/ai
4. ((haemosta$ or hemosta$ or antihaemorrhag$ or antihemorrhag$) adj5 (drug$ or agent$ or treat$ or therap$)).tw.
5. (antifibrinolytic$ or coagulat$ factor$ or clotting factor$ or aminocaproic acid or 6- aminocaproic acid or tranexamic acid or
aprotinin or factor VII$ or factor 7 or factor 7a or NovoSeven or thrombin inhib$ or argatroban).tw,nm.
6. platelet transfusion/
7. blood component transfusion/
8. blood platelets/ and (infus$ or transfus$).tw.
9. ((platelet$ or thrombocyte$ or blood component$) adj5 (transfus$ or infus$)).tw.
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11. exp basal ganglia hemorrhage/ or intracranial hemorrhages/ or cerebral hemorrhage/ or intracranial hemorrhage, hypertensive/
12. ((brain$or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or stroke or apoplex$) adj5 (h?emorrhag$
or h?ematoma$ or bleed$)).tw.
13. 11 or 12 or (ICH or ICHs).tw.
14. 10 and 13
15. Randomized Controlled Trials as Topic/
16. random allocation/
17. Controlled Clinical Trials as Topic/
18. control groups/
19. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
20. double-blind method/
21. single-blind method/
22. Placebos/
23. placebo effect/
24. Drug Evaluation/
25. Research Design/
26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. clinical trial.pt.
29. random$.tw.
30. (controlled adj5 (trial$ or stud$)).tw.
31. (clinical$ adj5 trial$).tw.
32. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
33. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
34. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
35. placebo$.tw.
36. controls.tw.
37. or/15-36
38. 14 and 37
39. exp animals/ not humans.sh.
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40. 38 not 39
Appendix 3. Embase Ovid (1974 to 27 November 2017)
1. exp hemostatic agent/ or exp antifibrinolytic agent/ or exp blood clotting factor/ or exp thrombin inhibitor/
2. hemostasis/
3. exp blood clotting/
4. thrombocyte activation/
5. 2 or 3 or 4
6. drug effect/ or dt.fs.
7. 5 and 6
8. ((haemosta$ or hemosta$ or antihaemorrhag$ or antihemorrhag$) adj5 (drug$ or agent$ or treat$ or therap$)).tw.
9. (antifibrinolytic$ or coagulat$ factor$ or clotting factor$ or aminocaproic acid or 6- aminocaproic acid or tranexamic acid or
aprotinin or factor VII$ or factor 7 or factor 7a or NovoSeven or thrombin inhib$ or argatroban).tw.
10. thrombocyte transfusion/
11. blood component therapy/
12. exp thrombocyte/ and (infus$ or transfus$).tw.
13. ((platelet$ or thrombocyte$ or blood component$) adj5 (transfus$ or infus$)).tw.
14. 1 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. basal ganglion hemorrhage/ or brain hemorrhage/ or brain ventricle hemorrhage/ or cerebellum hemorrhage/
16. ((brain$or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or stroke or apoplex$) adj5 (h?emorrhag$
or h?ematoma$ or bleed$)).tw.
17. 15 or 16 or (ICH or ICHs).tw.
18. 14 and 17
19. randomized controlled trial/
20. “randomized controlled trial (topic)”/
21. Randomization/
22. Controlled Study/
23. control group/
24. exp clinical trial/
25. Double Blind Procedure/
26. Single Blind Procedure/ or triple blind procedure/
27. placebo/
28. drug dose comparison/
29. drug comparison/
30. “types of study”/
31. random$.tw.
32. (controlled adj5 (trial$ or stud$)).tw.
33. (clinical$ adj5 trial$).tw.
34. ((control or treatment or experiment$ or interventionl) adj5 (group$ or subject$ or patient$)).tw.
35. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
36. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
37. placebo$.tw.
38. controls.tw.
39. or/19-38
40. 18 and 39
41. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not
(human/ or normal human/ or human cell/)
42. 40 not 41
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Appendix 4. US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov
Study Type: Intervention
Study results: All studies
Recruitment: All studies
Age group: Adults & seniors
Condition: (cerebral haemorrhage OR intracerebral haemorrhage OR intracranial haemorrhage OR intraparenchymal haemorrhage
OR parenchymal haemorrhage OR intraventricular haemorrhage OR haemorrhagic stroke OR ICH OR intracerebral bleed)
Intervention (performed as four separate searches, and then de-duplicated, due to the word limit for search criteria): haemostatics
OR haemostasis OR haemostatic agents OR haemostatic therapy OR haemostatic treatment OR antihaemorrhagic agent OR anti-
haemorrhagic therapy OR antihaemorrhagic treatment OR antihaemorrhage agent OR antihaemorrhage therapy OR blood clotting
OR blood coagulation factors OR blood coagulation OR coagulation factors OR thrombin OR platelet activation OR thrombocyte
activation OR platelet transfusion OR blood component transfusion OR thrombocyte transfusion OR antifibrinolytic agents OR
antifibrinolysis OR tranexamic acid OR aminocaproic acid OR 6-aminocaproic acid OR aprotinin OR factor VIIa OR factor VII OR
Factor 7a OR factor 7 or NovoSeven Or argatroban OR thrombin inhibitor OR desmopressin OR fresh frozen plasma OR FFP OR
prothrombin complex concentrates OR PCC
Appendix 5. World Health Organization (WHO) International Clinical Trials Registry Platform
(ICTRP)
Condition: brain haemorrhage OR cerebral haemorrhage OR intracerebral haemorrhage OR intracranial haemorrhage OR intra-
parenchymal haemorrhage OR intraventricular haemorrhage OR cerebellar haemorrhage OR parenchymal haemorrhage OR infraten-
torial haemorrhage OR supratentorial haemorrhage OR basal ganglia haemorrhage OR basal ganglion haemorrhage OR thalamic
haemorrhage OR putaminal haemorrhage OR posterior fossa haemorrhageOR hemispheric haemorrhage OR haemorrhagic stroke OR
haemorrhagic apoplexy brain haematomaOR cerebral haematomaOR intracerebral haematomaOR intracranial haematomaOR intra-
parenchymal haematoma OR intraventricular haematoma OR cerebellar haematoma OR parenchymal haematoma OR infratentorial
haematoma OR supratentorial haematoma OR basal ganglia haematoma OR basal ganglion haematoma OR thalamic haematoma OR
putaminal haematomaORposterior fossa haematomaORhemispheric haematomaORbrain bleedOR cerebral bleedOR intracerebral
bleed OR intracranial bleed OR intraparenchymal bleed OR parenchymal bleed OR intraventricular bleed OR cerebellar bleed OR
infratentorial bleed OR supratentorial bleed OR basal ganglia bleed OR putaminal bleed OR posterior fossa bleed OR hemispheric
bleed OR ICH OR ICHs
Intervention: haemostatics OR haemostasis OR haemostatic agents OR haemostatic therapy OR haemostatic treatment OR anti-
haemorrhagic agent OR antihaemorrhagic therapy OR antihaemorrhagic treatment OR antihaemorrhage agent OR antihaemorrhage
therapy OR antihaemorrhage treatment OR blood clotting OR blood coagulation factors OR blood coagulation OR coagulation
factors OR thrombin OR platelet activation OR thrombocyte activation OR platelet transfusion OR blood component transfusion OR
thrombocyte transfusion ORantifibrinolytic agents OR antifibrinolysis OR tranexamic acidOR aminocaproic acidOR6-aminocaproic
acid OR aprotinin OR factor VIIa OR factor VII OR Factor 7a OR factor 7 or NovoSeven Or argatroban OR thrombin inhibitor OR
desmopressin OR fresh frozen plasma OR FFP OR prothrombin complex concentrates OR PCC
WH A T ’ S N E W
Last assessed as up-to-date: 27 November 2017.
Date Event Description
10 December 2017 New search has been performed • Title modified.
• Inclusion criteria clarified to include participants
with stroke due to intracerebral haemorrhage
accompanied by any sort of antithrombotic drug use.
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(Continued)
• Inclusion criteria clarified to allow placebo,
open control, or active comparators.
• Literature and trial register search strategies
updated to November 2017.
• Stratification of analyses by antithrombotic use.
• We added six new trials and data from a further
334 participants, for a total of 12 trials and 1732
participants.
10 December 2017 New citation required and conclusions have changed • Our new conclusion is that platelet transfusion
seems hazardous in comparison to standard care for
adults with antiplatelet-associated acute spontaneous
intracerebral haemorrhage.
• We remain unable to draw firm conclusions
about the efficacy and safety of blood clotting factors
and antifibrinolytic drugs for acute spontaneous
intracerebral haemorrhage.
H I S T O R Y
Protocol first published: Issue 2, 2006
Review first published: Issue 3, 2006
Date Event Description
24 June 2013 Amended Co-authors added
29 June 2009 New citation required and conclusions have changed In comparison to the previous version of this review, haemo-
static drugs no longer significantly reduced death or depen-
dence after acute spontaneous intracerebral haemorrhage
29 June 2009 New search has been performed Updated with the addition of 841 people randomised in the
FAST trial
8 July 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
RA-SS registered the title, developed the original protocol, and wrote the first two versions of the review. All authors revised the protocol.
RA-SS and ZKL screened the title and abstracts of potentially eligible studies. RA-SS and NS reviewed potentially eligible studies in
full, appraised their risk of bias, extracted data from them, and obtained further data from study authors. RA-SS and NS updated the
review. PB and TS edited and provided comments on the review. RA-SS is responsible for the final version and is the guarantor.
D E C L A R A T I O N S O F I N T E R E S T
RA-SS: none known.
ZKL: none known.
PB: none known.
TS declared intellectual competing interests due to his involvement with some included RCTs (Mayer 2005a; Mayer 2005b; Mayer
2006; Mayer 2008 (FAST); Steiner 2016 (INCH)). TS had no role in study selection, assessment and data extraction with regard to
these studies.
NS: none known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• Title modified.
• Inclusion criteria clarified to include participants with stroke due to intracerebral haemorrhage accompanied by any sort of
antithrombotic drug use.
• Inclusion criteria clarified to allow placebo, open control, or active comparators.
• Literature and trial register search strategies updated (see Appendix 1; Appendix 2; Appendix 3; Appendix 4; Appendix 5). Some
of the names of the databases have been changed, some databases have been superceded, and we abandoned searches of other
databases: CenterWatch Clinical Trials Listing Service (www.centerwatch.com); Computer Retrieval of Information on Scientific
Projects (crisp.cit.nih.gov); NIH Clinical Research Studies Database (clinicalstudies.info.nih.gov); Stroke Trials Directory (
www.strokecenter.org/trials); and Trials Central (www.trialscentral.org/ClinicalTrials.asp) were not searched; pharmaceutical
companies were not contacted.
• Introduction of new secondary outcomes: death from any cause (categorised into early (< 7 days) and late (between 7 days and
the end of follow-up) if possible), quality of life, mood, cognitive function.
• Stratification of analyses by antithrombotic use and intended surgery.
• New and ongoing trials added.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Aminocaproic Acid [∗therapeutic use]; Antifibrinolytic Agents [adverse effects; ∗therapeutic use]; Cerebral Hemorrhage [∗drug therapy;
mortality]; Factor VIIa [adverse effects; ∗therapeutic use]; Hemostasis; Hemostatics [∗therapeutic use]; Randomized Controlled Trials
as Topic; Recombinant Proteins [adverse effects; therapeutic use]
MeSH check words
Adult; Humans
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